Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mBio
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Research Article | Host-Microbe Biology

Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways

Melinda A. Engevik, Berkley Luk, Alexandra L. Chang-Graham, Anne Hall, Beatrice Herrmann, Wenly Ruan, Bradley T. Endres, Zhongcheng Shi, Kevin W. Garey, Joseph M. Hyser, James Versalovic
Sabina Gorska, Invited Editor, Nathalie Pujol, Editor
Melinda A. Engevik
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Melinda A. Engevik
Berkley Luk
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Berkley Luk
Alexandra L. Chang-Graham
cDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Hall
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne Hall
Beatrice Herrmann
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenly Ruan
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley T. Endres
dDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhongcheng Shi
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin W. Garey
dDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin W. Garey
Joseph M. Hyser
cDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Versalovic
aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA
bDepartment of Pathology, Texas Children’s Hospital, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabina Gorska
Polish Academy of Sciences, Institute of Immunology and Experimental Therapy
Roles: Invited Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathalie Pujol
CIML
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/mBio.01087-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Much remains unknown about how the intestinal microbiome interfaces with the protective intestinal mucus layer. Bifidobacterium species colonize the intestinal mucus layer and can modulate mucus production by goblet cells. However, select Bifidobacterium strains can also degrade protective glycans on mucin proteins. We hypothesized that the human-derived species Bifidobacterium dentium would increase intestinal mucus synthesis and expulsion, without extensive degradation of mucin glycans. In silico data revealed that B. dentium lacked the enzymes necessary to extensively degrade mucin glycans. This finding was confirmed by demonstrating that B. dentium could not use naive mucin glycans as primary carbon sources in vitro. To examine B. dentium mucus modulation in vivo, Swiss Webster germfree mice were monoassociated with live or heat-killed B. dentium. Live B. dentium-monoassociated mice exhibited increased colonic expression of goblet cell markers Krüppel-like factor 4 (Klf4), Trefoil factor 3 (Tff3), Relm-β, Muc2, and several glycosyltransferases compared to both heat-killed B. dentium and germfree counterparts. Likewise, live B. dentium-monoassociated colon had increased acidic mucin-filled goblet cells, as denoted by Periodic Acid-Schiff-Alcian Blue (PAS-AB) staining and MUC2 immunostaining. In vitro, B. dentium-secreted products, including acetate, were able to increase MUC2 levels in T84 cells. We also identified that B. dentium-secreted products, such as γ-aminobutyric acid (GABA), stimulated autophagy-mediated calcium signaling and MUC2 release. This work illustrates that B. dentium is capable of enhancing the intestinal mucus layer and goblet cell function via upregulation of gene expression and autophagy signaling pathways, with a net increase in mucin production.

IMPORTANCE Microbe-host interactions in the intestine occur along the mucus-covered epithelium. In the gastrointestinal tract, mucus is composed of glycan-covered proteins, or mucins, which are secreted by goblet cells to form a protective gel-like structure above the epithelium. Low levels of mucin or alterations in mucin glycans are associated with inflammation and colitis in mice and humans. Although current literature links microbes to the modulation of goblet cells and mucins, the molecular pathways involved are not yet fully understood. Using a combination of gnotobiotic mice and mucus-secreting cell lines, we have identified a human-derived microbe, Bifidobacterium dentium, which adheres to intestinal mucus and secretes metabolites that upregulate the major mucin MUC2 and modulate goblet cell function. Unlike other Bifidobacterium species, B. dentium does not extensively degrade mucin glycans and cannot grow on mucin alone. This work points to the potential of using B. dentium and similar mucin-friendly microbes as therapeutic agents for intestinal disorders with disruptions in the mucus barrier.

INTRODUCTION

The mucus layer is the first point of contact between the gut microbiota and the host. Intestinal mucus is composed primarily of the gel-forming secreted mucin MUC2 synthesized by intestinal goblet cells (1–3). Mucins form homodimers in the endoplasmic reticulum (ER) and are O-glycosylated in the Golgi apparatus. Glycosylation is a key step to produce functionally mature mucus, and mucin O-linked glycans account for up to 80% of the mucin protein’s molecular weight (4–8). Mature glycosylated mucins are packaged into mucus granules that can be secreted constitutively or released after stimulation by specific agonists (3). The intestinal mucus layer is important for overall health since disruption of this boundary can contribute to intestinal inflammation (1, 9–13). For example, ulcerative colitis (UC) patients have reduced synthesis and secretion of mucins, altered O-glycosylation, decreased mucus thickness, and increased bacterial penetration of the mucus barrier (9–11, 14). These findings are reflected in mouse models as well, where a loss of MUC2 proteins or their glycans results in colitis (2, 15–21). Due to their beneficial properties, including mucus modulation, bifidobacteria have been proposed as a potential treatment for human diseases characterized by an impaired mucus layer (22–28). Bifidobacterium strains have been reported to promote remission for UC patients (29, 30), lending credence to the concept of using bifidobacteria as a potential therapeutic agent for mucin-related disorders.

Bifidobacterium species are among the first colonizers of the gastrointestinal (GI) tract (31–39). Although bifidobacteria represent only 3 to 6% of the healthy adult fecal microbiota (40, 41), their presence has been associated with numerous health benefits (29, 30, 42–63). However, the molecular mechanisms that underlie these positive effects, which appear to be relatively strain specific, remain unclear (64, 65). Therefore, it is important to understand which molecular strategies are employed by select species in order to characterize their individual effects on the host. In particular, bifidobacteria are known to adhere to intestinal mucins and colonize the mucus layer of the GI tract (66–68). Close proximity of bacterium and host cells may promote health-mediating effects of bifidobacteria (67–70). Although bifidobacteria modulate MUC2 levels (24–27), several well-characterized Bifidobacterium species harbor glycosyl hydrolases which can extensively degrade mucin glycans (7, 71–81). While these mucin-degrading enzymes are likely important in GI niche development, the ability of select bifidobacterial species to degrade mucin glycans may be unfavorable when there is diminished mucin production, such as during colitis. These findings emphasize the need to characterize the nature of the mucin-modulating capacity of Bifidobacterium strains. Our model strain of Bifidobacterium dentium was isolated from the feces of healthy infants and adults (38, 82–85) and has been observed in healthy adults at a relative abundance of 0.7% in studies published by the Human Microbiome Project Consortium (86–90). While much work has addressed the effects of several Bifidobacterium species on the host, few studies have examined how B. dentium modulates the intestinal environment.

Using gnotobiotic mice, we have identified that B. dentium adheres to intestinal mucus and colonizes the mucus layer of the colon. In contrast to other well-characterized Bifidobacterium strains which contain numerous mucin-degrading glycosyl hydrolases, B. dentium harbors only 4 glycosyl hydrolases involved in mucin degradation. This biochemical feature is reflected by the inability of B. dentium to grow with mucin as the sole carbon source. We show that colonization by B. dentium is associated with increased Muc2 expression and MUC2 synthesis, in addition to alterations in glycosyltransferases and terminal glycans. We have positively identified two B. dentium-secreted compounds that modulate goblet cells, as follows: acetate, which stimulates MUC2 synthesis, and γ-aminobutyric acid (GABA), which promotes autophagy and calcium mobilization to release stored mucin granules from intestinal goblet cells. This study is among the first to characterize B. dentium mucus modulation and points to the role of B. dentium as a mucin builder (versus the mucin degraders and mucin maintainers) and a possible therapeutic agent for diseases with disrupted mucus barriers.

RESULTS

B. dentium adheres to intestinal MUC2.Adhesion to the intestinal mucus layer is considered a prerequisite for colonization by mucosa-associated bacteria and represents a selection criterion for probiotic microbes (91). Given the importance of intestinal mucus at the microbe-mammal interface, we sought to identify whether Bifidobacterium dentium could adhere to and modulate intestinal mucins. To determine the adhesion capabilities of B. dentium to intestinal mucus, B. dentium was fluorescently tagged with carboxyfluorescein diacetate- succinimidyl ester (CFDA-SE) and incubated for 1 h with purified germfree mouse MUC2 at various optical densities (ODs) (Fig. 1A and B). For comparison, we included CFDA-SE-tagged Bifidobacterium species that are known to adhere to mucins, including B. breve, B. bifidum, B. longum subsp. longum, and B. longum subsp. infantis (67, 68, 92). Bifidobacterium strains varied in their ability to adhere to mucins, with B. breve exhibiting the greatest degree of adhesion and B. longum subsp. infantis the lowest degree of adhesion. B. dentium adhered to MUC2 to a similar degree as B. longum subsp. longum, indicating the comparable ability of B. dentium to adhere to mouse MUC2. Additionally, B. dentium colocalized with MUC2 in the mucus-producing human cell line LS174T, as observed by immunofluorescence and scanning electron microscopy (SEM) (Fig. 1C and D). These data indicate that B. dentium, similar to other well-characterized bifidobacteria, is able to adhere to mouse and human MUC2.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

B. dentium adheres to intestinal Muc2. (A) CFDA-SE fluorescently tagged B. dentium, B. breve, B. bifidum, B. longum subsp. longum, and B. longum subsp. infantis adhesion to purified germfree mouse cecal MUC2 as denoted by fluorescence (excitation/emission, 488/528 nm) (n = 8/group, representative of 3 independent experiments. (B) Representative immunofluorescence images (×600 magnification, scale bar = 50 μm) of CFDA-SE-tagged B. dentium adhesion to germfree MUC2. (C). Representative images (×200 magnification, scale bar = 50 μm) of B. dentium (green) colocalizes with MUC2 (red) in human LS174T goblet cell by immunostaining; scale bar = 50 μm. DAPI, 4′,6-diamidino-2-phenyindole. (D) Scanning electron microscopy (SEM) images of B. dentium (green) and mucus (red) in LS174T cells (color added artificially, scale bar = 5 μm).

B. dentium harbors relatively few mucin-related glycosyl hydrolases.A number of Bifidobacterium species harbor extensive glycosyl hydrolases (GHs) that are able to degrade mucin glycans (93). To define whether B. dentium was capable of degrading mucin glycans, we examined glycosyl hydrolases in B. dentium compared to glycosyl hydrolases across other Bifidobacterium species. In silico analysis of several Bifidobacterium genomes revealed that B. dentium genomes contain a greater number of glycosyl hydrolases (87.5 ± 0.7) than do strains of B. bifidum (45.1 ± 3.8), B. breve (50.9 ± 7.4), B. longum (59.4 ± 8.4), and B. longum subsp. infantis (59.6 ± 8.8) (Fig. 2A). Of these glycosyl hydrolases, only select families are involved in mucin degradation (Fig. 2B to N). The following glycosyl hydrolase families are involved in the degradation of mucin O-linked glycans: GH33 (sialidase), GH101 and GH129 (N-acetylgalactosaminidases), GH84, GH85, and GH89 (N-acetylglucosaminidases), GH20 (galactosidase), GH95 and GH29 (fucosidase), and GH2 and GH42 (galactosidase) (Fig. 2B to L). Additionally, the glycosyl hydrolase families GH38 and GH125 (mannosidases) are involved in N-linked glycan degradation (Fig. 2M and N). Our in silico analysis demonstrated the presence of a GH33 family member, which removes the terminal sialic acid residue, in several Bifidobacterium species (Fig. 2B). In contrast, the B. dentium Bd1 or DSM 20436 genomes do not encode any GH33 enzymes, indicating the inability to remove sialic acid. Some bifidobacteria also code for GH101 and GH129, which includes a cell wall-anchored endo-α-N-acetylgalactosaminidase that can remove entire glycan structures from the mucin protein (81, 94–98) (Fig. 2C and D). However, B. dentium did not harbor these glycosyl hydrolase families. We also detected N-acetylgalactosaminidases (GH84, GH85, and GH89) in several Bifidobacterium species, particularly the B. bifidum group (Fig. 2E to G). GH84, GH85, and GH89 were also absent in the B. dentium genome. Of note, B. dentium was predicted to remove α- and β-linked galactose (GH2 and GH42), α-fucose (GH29), and mannose (GH125) (Fig. 2G, I, K, and M). These findings indicate that B. dentium has a limited capacity to degrade mucin glycans.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

B. dentium harbors few glycosyl hydrolases and is unable to grow on Muc2 alone. Several bifidobacterial genomes were screened for glycosyl hydrolases using the CAZy database. (A to N) Data are presented in terms of copy number for glycosyl hydrolase (GH) families in the whole genome (A) and predicted to be involved in O-linked (B to L) and N-linked (M and N) mucin degradation. (O) B. dentium was grown in LDMIV with or without glucose or purified MUC2 from germfree cecal contents or human goblet cell line LS174T and HT29-MTX. (P) B. dentium was also grown without glucose in the presence of carbohydrates found in mucins. n = 4 groups/treatment, repeated 4 independent times. *, P < 0.05, one-way ANOVA.

Since B. dentium does not encode GH33, which removes terminal sialic acid groups and provides access to underlying carbohydrates in the glycan, we hypothesized that B. dentium would not be able to release carbohydrate residues from MUC2 and use them as a growth source. To address this question, B. dentium was grown in a fully defined medium (lactic acid bacteria defined medium IV [LDMIV]) with the carbon source (100 mM glucose) removed (Fig. 2O). Supplementation of purified germfree cecal MUC2 or MUC2 derived from the human mucin-producing cell lines LS174T or HT29-MTX at 1 mg/ml did not enhance B. dentium growth in LDMIV without glucose. Next, we examined whether B. dentium could grow in minimal medium in the presence of free oligosaccharides that are typically found in mucin (Fig. 2P). The addition of mannose and, to some degree, galactose was able to restore the growth of B. dentium. However, B. dentium was unable to grow on fucose, N-acetylglucosamine, N-acetylgalactosamine, or sialic acid as primary carbon sources. These data further support the idea that B. dentium does not extensively degrade mucin glycans and cannot use them as a fuel source.

B. dentium colonizes the intestinal mucus layer in vivo.Based on our in vitro data demonstrating that B. dentium adheres to purified MUC2 and existing literature demonstrating the mucus-modulatory effect of Bifidobacterium species, we next examined the effect of B. dentium on the intestinal mucus layer in a gnotobiotic model. Adult germfree Swiss Webster mice (male, n = 21; female, n = 23) were orally gavaged with either sterile de Man-Rogosa-Sharpe (MRS) medium, live B. dentium MRS cultures (2 × 108 bacteria), or heat-killed B. dentium (2 × 108 bacteria) every other day for 1 week. To prevent cross-contamination, mice were housed in separate isolators. For comparison, age-matched Swiss Webster specific-pathogen-free (SPF) mice that have a complex murine microbiota were included as controls. Microbe colonization was examined by tissue Gram staining, fluorescence in situ hybridization (FISH), quantitative real-time PCR (qPCR), and conventional plating on bacteriologic medium (Fig. 3). Gram stains of SPF mice indicate a robust microbial community residing in the mucus layer above the epithelium (Fig. 3A). Multiple bacterial morphologies were present in the SPF mice, including cocci and rods (Fig. 3A, inset). Microbial distribution was confirmed by FISH with a probe recognizing diverse bacteria (universal 16S rRNA gene-based probe) (Fig. 3B). In contrast to SPF mice, germfree mice exhibited no bacterial stains by Gram stain or FISH, while B. dentium-monoassociated mice exhibited classic bifid-shaped microbes in the mucus layer adjacent to the intestinal epithelium (Fig. 3A and B). Negligible bacterial staining was observed by Gram stain or FISH in mice treated with heat-killed B. dentium (Fig. 3A and B). Colonization of B. dentium was further confirmed using microbiologic plating of stool on MRS plates and qPCR of stool extract genomic DNA (gDNA) with B. dentium-specific primers. Data obtained by qPCR and microbial cultures with CFU resulted in calculations of approximately 7.2 × 107 ± 1 × 107 bacteria per gram in B. dentium-monoassociated mouse stool, with no observable CFU for germfree or heat-killed B. dentium groups. These findings indicate that live B. dentium can stably colonize the mucus layer of germfree mice.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

B. dentium colonizes gnotobiotic mouse colon. (A and B) Representative images of tissue Gram stains (×200 magnification, scale bar = 50 μm) (A) and fluorescence in situ hybridization (FISH) (×400 magnification, scale bar = 50 μm) (B) of the midcolon of germfree (n = 10), live B. dentium-monoassociated (n = 10), heat-killed B. dentium-treated (n = 10) and mice with a complete gut microbiota (specific pathogen free [SPF]) (n = 10). Insets reveal higher-magnification (×60) images of bacterial morphology.

Gut microbes are known to influence morphological parameters, including weight, cecum size, intestinal parameters, and development of the lamina propria (99–101). To determine if colonization by B. dentium influences overall mouse weight, mice were weighed on day 17 after monoassociation (Fig. 4A). No significant differences were observed in terms of mouse body mass between germfree, live, or heat-killed B. dentium-monoassociated groups (day 17 germfree, 40.5 ± 5.6 g; live B. dentium, 42.5 ± 4.8 g; heat-killed B. dentium, 39.5 ± 5.3 g). Germfree mice are characterized by an accumulation of mucins, proteins, and carbohydrates which results in abnormally large cecum size (102, 103). The morphologic difference between germfree and conventionally colonized mouse cecum is associated with the absence of mucus-degrading intestinal bacteria (104, 105). Cecal weights revealed that B. dentium monoassociation did not restore cecum size, as both germfree, live, and heat-killed B. dentium-colonized mice exhibited significantly longer ceca than their conventionally colonized counterparts (Fig. 4B). This finding is consistent with the prediction that B. dentium cannot extensively degrade mucins, and several species are likely to be necessary to modulate mucus sufficiently to affect cecum size.

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

B. dentium-monoassociated mice yield increased numbers of intestinal goblet cells. (A) Weight measured at day 17 of germfree (black dots, n =40), live B. dentium-monoassociated (green dots, n =40), and heat-killed B. dentium treated (teal dots, n =10) mice. (B and C) Measurement of cecum weights (B) and quantification of goblet cells per colonic crypt by Fiji analysis (C) of germfree (n = 20 mice), live B. dentium-monoassociated (n = 20), heat-killed B. dentium (n = 10), and specific-pathogen-free (SPF) (n = 10) mice. All data are presented as averages of 3 images per section/mouse. (D) H&E stains (×200 magnification, scale bar = 50 μm) of midcolon from germfree, live B. dentium-monoassociated, heat-killed B. dentium-treated, and SPF mice. n = 10 mice/group. *, P < 0.05, one-way ANOVA.

To assess the effects of B. dentium colonization on intestinal morphology, we examined intestinal dimensions and architecture from hematoxylin and eosin (H&E) staining (Fig. 4C and D). No significant differences were observed for colon diameters or colon lengths between any of the groups (data not shown). H&E staining found no differences in crypt depths between germfree, live, or heat-killed B. dentium-colonized mice. However, H&E staining indicated that B. dentium-colonized mice exhibited an increase in filled goblet cell numbers per crypt relative to germfree mice and heat-killed B. dentium-treated mice (Fig. 4C and D).

Goblet cells are modulated by B. dentium colonization.Next, we sought to define the effects of B. dentium monoassociation on goblet cell maturation and function. Compared to germfree mice and heat-killed B. dentium controls, B. dentium-colonized mice exhibited increased expression of Krüppel-like family of zinc-finger transcription factor 4 (Klf4), a goblet cell-specific differentiation factor (106) (Fig. 5A). Goblet cells are known to produce a number of important mucosal defense factors, such as resistin-like molecule-beta (Relm-β) and trefoil factor 3 (Tff3) (107). Both Relm-B and Tff3 expression levels were increased in B. dentium-colonized colons compared with those of germfree or heat-killed B. dentium controls (Fig. 5A). MUC2 is the major gel-forming mucin protein secreted by intestinal goblet cells. Similar to other markers of goblet cells, Muc2 mRNA was also increased in B. dentium-monoassociated mice compared with germfree and heat-killed B. dentium controls (Fig. 5A). Of note, a trend toward increased expression of Relm-β and Muc2 was observed in heat-killed B. dentium-treated mice. Although not significant, this may point to a complementary role of B. dentium surface proteins in modulating goblet cells. Several cytokines are associated with increased mucus production, most notably interleukin-22 (IL-22), IL-33, and IL-13 (108–111). Interestingly, no changes were observed in any of these mucin-regulating cytokines (Fig. 5B), indicating that B. dentium may be modulating mucin production through secreted factors that affect the epithelium, rather than by stimulating the immune system.

FIG 5
  • Open in new tab
  • Download powerpoint
FIG 5

B. dentium-monoassociated mice have increased expression of goblet cell marker genes without corresponding changes in mucin-modulating cytokines. (A to C) qPCR analysis of germfree (black dots, n = 20), live B. dentium-monoassociated (green dots, n = 20), and heat-killed B. dentium-treated (teal dots, n = 10) colon for goblet cell markers (A), mucin-inducing cytokines (B), and goblet cell glycosyltransferase gene expression (C). All expression was normalized to GAPDH. *, P < 0.05, one-way ANOVA.

B. dentium modulates glycosylation of the intestinal mucus layer.Mucin proteins are heavily O-glycosylated by glycosyltransferases within the goblet cell ER and Golgi. Glycosylation is influenced by colonization status, as intestinal bacteria are known drivers of mucin O-glycosylation (112–117). As a result, we examined changes in goblet cell glycosyltransferases in the presence of B. dentium (Fig. 5C). An examination of glycosyltransferases in B. dentium-monoassociated mice found significantly increased gene expression of several glycosyltransferases by qPCR compared with germfree controls. Increases in B. dentium-monoassociated colons compared with germfree controls were observed in the following glycosyltransferases: B3gnt6 (β-1,3-N-acetylglucosaminyltransferase 6), C1galt1 (β-1,3-galactosyltransferase 1), C2gnt [glucosaminyl (N-acetyl)transferase 1], Fut2 (fucosyltransferase 2), C2GnT1 [glucosaminyl (N-acetyl)transferase 1], and St6gal1 (ST6 N-acetylgalactosaminide α-2,6-sialyltransferase). No change was observed in C2gnt3 [glucosaminyl (N-acetyl)transferase 3]. Increased St6gal1 was of interest, as it appends on terminal sialic acid residues to mucin glycans. The addition of sialic acid alters the charge of the mucus and enhances the potential for mucus to resist attack by bacterial enzymes (118, 119). Mirroring the increased expression of Muc2, B. dentium-treated mice also had increased periodic acid-Schiff–alcian blue (PAS-AB)-positive goblet cells, which identifies negatively charged mucins compared with germfree and heat-killed B. dentium-treated mice (Fig. 6A and D). Immunostaining corresponded with the PAS-AB results and demonstrated increased MUC2 protein in B. dentium-monoassociated mice compared with germfree and heat-killed B. dentium controls (Fig. 6B and E), indicating that live B. dentium can upregulate MUC2 in vivo. An examination of terminal mucin sugars using lectins revealed no differences between the terminal sugars fucose, mannose, galactose, N-acetyl- d-glucosamine (GlcNAc), N-acetyl-d-galactosamine (GalNAc) in B. dentium-colonized mice (live or dead), and germfree mice (data not shown). Consistent with increased St6gal1, which appends on sialic acid, B. dentium-colonized mice exhibited increased amounts of α-2,6-linked sialic acid in intestinal mucins compared with germfree and heat-killed B. dentium controls (Fig. 6C and F). These results indicate that B. dentium alone cannot degrade terminal sialic acid and thus cannot efficiently degrade the mucus layer.

FIG 6
  • Open in new tab
  • Download powerpoint
FIG 6

B. dentium-monoassociated mice have increased colonic Muc2 production. (A) Representative images (×200 magnification, scale bar = 50 μm) of PAS-AB stains of germfree, live B. dentium-monoassociated, and heat-killed B. dentium mouse midcolon. (B) Immunostaining of MUC2 (green) in mouse midcolon (×200 magnification, scale bar = 50 μm) counterstained with Hoechst. (C) FITC-labeled lectins (Vector Labs) were used to identify terminal carbohydrates, including sialic acid (also known as N-acetylneuraminic acid or NAN) (white) in mouse midcolon (×200 magnification, scale bar = 50 μm) counterstained with Hoechst. (D to F) Quantification of staining intensity per crypt or FITC fluorescence per crypt by Fiji. Fiji analysis was based on 5 representative images per mouse, n = 10 mice/group. *, P < 0.05, one-way ANOVA. AU, arbitrary units.

B. dentium stimulates autophagy-mediated Ca2+ signaling and mucus expulsion.Based on our in vivo data, which demonstrated significant changes in MUC2 production in response to live B. dentium, we speculated that secreted factors play a role in modulating goblet cell function. Similar to other bifidobacteria, the B. dentium genome harbors the machinery required to generate acetate (65, 120) (KEGG Pathway, map 01120), a short-chain fatty acid that has also been shown to stimulate Muc2 expression (121, 122). We have also previously shown that B. dentium secretes 3.4 ± 0.4 mg/ml GABA (87), and other groups have found that activation of GABA type A (GABAA) receptors stimulates the release of stored mucin granules (123). To determine if B. dentium secretes factors that increase MUC2 synthesis, we utilized the T84 intestinal epithelial cell line, which can form goblet-like cells with MUC2-containing secretory granules (124). T84 cells harbor GABA receptors (125, 126) and an acetate receptor (GPR43) (127), allowing us to examine the effects of these compounds on MUC2 levels. The addition of B. dentium-conditioned medium resulted in increased MUC2 by immunostaining compared to medium controls (Fig. 7A). Moreover, the addition of acetate, but not GABA or heat-killed B. dentium, increased MUC2 staining. At the mRNA level, the addition of increasing concentrations of B. dentium-conditioned medium, as well as 5 mM acetate, resulted in increased levels of MUC2 (Fig. 7B). This result indicates that B. dentium can secrete products, such as acetate, that are capable of increasing MUC2 synthesis.

FIG 7
  • Open in new tab
  • Download powerpoint
FIG 7

B. dentium secretes products, including acetate, that increase human Muc2 production. (A) Immunostaining of MUC2 (green) and nuclear dye Hoechst (blue) in T84 cells treated with B. dentium-conditioned medium, 5 mM acetate, 2 mg/ml GABA, or 108 heat-killed B. dentium bacteria (×200 magnification, all scale bars [including magnified inset] = 50 μm). (B) qPCR analysis of MUC2 gene expression in response to increased concentrations of B. dentium-conditioned medium and acetate. n = 6 to 8 wells of T84/treatment group, with 3 independent experiments. *, P < 0.05, one-way ANOVA.

In addition to synthesizing MUC2, goblet cells release stored MUC2 granules in response to the proper stimuli. Work by Patel et al. has demonstrated that autophagy is required to elicit Ca2+ signaling within intestinal goblet cells (128), and that defects in autophagy (ATG5 deficiency) result in a loss of Ca2+ mobilization and accumulation of mucin granules within goblet cells. In parallel with these findings, multiple studies have found that Ca2+ signaling is required for the release of mucin-filled vacuoles (128–131). We examined a number of known autophagy markers by qPCR and found that B. dentium colonization was associated with increased expression of ATG16L, ATG5, Beclin1, LAMP2, and LC3 (Fig. 8A). To determine if B. dentium was capable of eliciting Ca2+ signaling and MUC2 release, we first created mucin-producing T84 cells that stably expressed the cytoplasmic genetically encoded Ca2+ indicator GCaMP6s using lentivirus transduction (132). We then incubated the T84 GCaMP6s cells with B. dentium FluoroBrite conditioned Dulbecco's modified Eagle medium (DMEM) and measured the relative cytoplasmic Ca2+ concentration using epifluorescence microscopy (Fig. 8B and C). The addition of B. dentium-conditioned medium significantly increased Ca2+ levels (Fig. 8C). Mucin release was quantified by the release of CFDA-SE-tagged proteins at 1 h (Fig. 8D and E) or by alcian blue staining of T84 cell supernatants after 24 h (Fig. 8F). Corresponding to Ca2+ signaling data, B. dentium-conditioned medium elicited mucin release (Fig. 8D to F). The results obtained with B. dentium conditioned medium (CM) were comparable to results obtained with calcium ionophore A21387. Notably, the intracellular calcium chelator BAPTA-AM [1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester)] prevented the secretion of mucin. Moreover, pretreatment with the autophagy inhibitor 3-methyladenine (3-MA) inhibited B. dentium stimulated-mucus release, indicating that B. dentium requires both autophagy and Ca2+ mobilization to promote mucin secretion (Fig. 8D and F). We also demonstrated that GABA stimulates mucin expulsion, an effect which can be partially inhibited by 3-MA and completely inhibited by BAPTA-AM (Fig. 8E and F). Acetate and heat-killed B. dentium had no effect on mucin expulsion (Fig. 8E and F), indicating that B. dentium-secreted products, including GABA, are capable of stimulating the release of MUC2 from goblet cells. Together, this work provides evidence that B. dentium is unable to degrade mucin glycans or proteins to an appreciable extent to support growth but can stimulate host mucin production and secretion to bolster the mucus barrier. This work highlights the unique nature of B. dentium as a “mucin builder” and potential therapeutic for mucin-related disorders.

FIG 8
  • Open in new tab
  • Download powerpoint
FIG 8

B. dentium activates autophagy and stimulates calcium signaling. (A) qPCR analysis of autophagy genes in germfree mice (black dots, n = 20), live B. dentium-monoassociated mice (green dots, n = 20), and heat-killed B. dentium-treated mice (n = 10 mice/group). (B) T84 cells transduced with the green fluorescent protein (GFP)-based calcium sensor GCaMP6s (×200 magnification). (C) Quantification of live imaging of T84 cells in response to medium (control) and B. dentium FluoroBrite conditioned DMEM over 3 h. n = 6 to 8 wells of T84/treatment group, with 3 independent experiments. (D and E) Release of CFDA-SE-tagged proteins measured at 1 h in response to B. dentium (Bd)-conditioned medium, heat-killed B. dentium, acetate, or GABA and inhibitors (calcium quencher BAPTA-AM and autophagy inhibitor 3-MA) or activators (calcium ionophore A21387). Fluorescent intensity determined by fluorescence absorbance at excitation 488 and emission 528. (F) Mucin content was measured in the supernatant by PAS-AB quantification using purified Muc2 as a standard. n = 8 wells of T84/treatment group, for 3 independent experiments. *, P < 0.05, one-way ANOVA; n.s., nonsignificant.

DISCUSSION

Herein, we describe the first gnotobiotic mouse model with a mucin-building, human-derived Bifidobacterium species, B. dentium. By studying monoassociated mouse models with human gut microbes adept at modulating intestinal mucus, we have gained new insights into the microbe-mammal interface. We demonstrate that B. dentium adheres to intestinal mucus and colonizes the mucus layer in vivo, but it does not harbor the genetic machinery required to significantly degrade the mucin glycans. We demonstrate that the presence of B. dentium correlates with significant increases in mucin gene expression as well as increased quantities of MUC2 protein. B. dentium-secreted products, such as acetate, were able to increase MUC2 production in vitro. B. dentium also releases products which regulate intestinal goblet cells, including GABA, which stimulates autophagy-mediated Ca2+ signaling and MUC2 release. These findings are supported by our in vivo findings of increased autophagy gene expression in B. dentium-colonized mice. We postulate that these factors work together in concert to mediate the mucin-building effects of B. dentium. Together, these findings suggest that B. dentium may be a desirable mucin builder Bifidobacterium species for the treatment of mucin-related disorders.

Our work is the first to provide conclusive evidence of Bifidobacterium species directly modulating MUC2 and glycosylation in vivo. Bifidobacteria are known to colonize the intestinal mucus layer, and this location has been speculated to allow for the optimal delivery of microbial metabolites to promote mucin production (43, 44, 59–61, 63, 133–135). Several studies point to the role of bifidobacteria in mucin maintenance in rats and mice with a complex gut microbiota (24–27, 136). The contributions of specific gut microbes is difficult to decipher in SPF animals, making the development of gnotobiotic mouse models attractive for studies of microbiome-mucus layer biology. Our work demonstrates that B. dentium is able to adhere to intestinal MUC2 and expands prior studies by reporting that B. dentium produces compounds that stimulate MUC2 synthesis. Our in vivo gnotobiotic mouse model and our in vitro T84 human cell model support this conclusion. In support of a specific role of secreted metabolites in stimulating mucus production, we found no differences in the cytokines known to stimulate intestinal mucus production (108, 109, 137–140). Additionally, our data using heat-killed B. dentium indicate that B. dentium surface components do not play a large role in modulating MUC2 in vivo or in vitro. Although lipoteichoic acids (LTA) from Gram-positive bacteria and other Toll-like receptor (TLR) agonists have been reported to modulate mucin production (141–147), we did not observe significant changes in MUC2 levels in response to B. dentium surface proteins. Single-cell sequencing indicates that mouse goblet cells exhibit low TLR2 expression compared to other cell types (Single Cell Portal; Broad Institute). We speculate that this observation may account for our lack of significant goblet cell modulation by our heat-killed bacteria. Our in vitro work in human T84 cells also indicated that heat-killed B. dentium has no effect of MUC2 synthesis or expulsion. This finding may be due to our T84 cell line model, and further studies are needed to assess B. dentium-mediated TLR activation in human goblet cells.

Based on our data, we speculate that B. dentium enhances mucus production via the secretion of microbial metabolites such as acetate and GABA. B. dentium does not contain the genes responsible for generating butyrate or propionate, but it is capable of synthesizing acetate (KEGG). As such, we speculate that the MUC2-modulating effects of B. dentium may be due in part to acetate production. Acetate may work through multiple pathways. According to single-cell sequencing of mouse intestinal epithelium, the acetate receptor GPR43 (also known as FFAR2) is highly expressed in goblet cells (Single Cell Portal; Broad Institute), and acetate may directly modulate GPR43 to stimulate MUC2 production. Additionally, acetate is known to lower the intestinal pH (148, 149), and the organization of MUC2 in goblet cells is triggered by low pH (150). Moreover, enteroendocrine cells in the intestine can be stimulated by low pH or GPR43 activation to secrete serotonin, which is also known to influence goblet cells (151–154). In addition to acetate, it is possible that B. dentium secretes other products that regulate MUC2 production. Another lactic acid-producing bacterium, Lactobacillus rhamnosus GG, secretes a 40-kDa protein, termed p40, which has 27 to 78% homology with CHAP domain-containing proteins secreted by various Bifidobacterium strains, including B. dentium (155). These compounds may also be involved in B. dentium-mediated mucin modulation.

In addition to promoting MUC2 synthesis, we demonstrate that B. dentium metabolites stimulate autophagy-mediated Ca+2 signaling and mucin release. MUC2 secretion and the renewal of the colonic mucus layer are essential for the protective function of mucins. Goblet cells can release stored mucin granules in response to autophagy and Ca2+-mobilizing agents, such as acetylcholine or other cholinergic agonists (144, 156–161). Patel et al. found that autophagy was required for mucin release, and ATG5-deficient mice were unable to release MUC2 (128). Moreover, another autophagy-deficient mouse model, ATG7 knockout mice, exhibited a diminished mucus layer and was more susceptible to dextran sulfate sodium (DSS)-induced colitis (161). We are the first to link bacterium-promoted autophagy with goblet cell mucin expulsion. Our work shows that B. dentium can stimulate autophagy-driven Ca2+ signaling. We also demonstrate that GABA is capable of eliciting mucin secretion, an effect which can be minimized by blocking the autophagy pathway by 3-MA. Interestingly, RELM-β, a compound secreted by goblet cells, has also been shown to act as a mucin secretagogue in the mouse colon and HT29-Cl.16E human gut cell lines (162). RELM-β is upregulated in response to B. dentium colonization in our model and may serve to further promote MUC2 expulsion in vivo.

Finally, we demonstrate that B. dentium is unique among several well-characterized human Bifidobacterium strains, as it is unable to extensively degrade mucin glycans. Although the CAZy database does not have GHs annotated for our B. dentium ATCC 27678 strain, a BioCyc Database Basic Local Alignment Search Tool (BLAST) search shows 99 to 100% homology between mucin-degrading GHs in B. dentium ATCC 27678 and B. dentium Bd1 (UniProt D2Q7E7 [GH29], D2Q5B6 [GH125], D2Q767 [GH2], and D2Q935 [GH42]), indicating that the Bd1 genome can be used as a proxy for ATCC 27678 analysis. Based on in silico analysis and in vitro experiments, Bifidobacterium species do not produce mucinases that can cleave the MUC2 mucin protein core (163). However, many bifidobacteria do synthesize mucin carbohydrate-cleaving glycosyl hydrolases (65, 164). These human gut species include Bifidobacterium scardovii, B. longum subsp. longum, B. longum subsp. infantis, B. breve, and B. bifidum (165). B. dentium does not contain genes of the GH33 sialidase family or genes of the GH101 or GH129 families that enable cleavage of mucin glycans from the mucin protein. Despite the fact that the B. dentium genome contains more GHs than the average Bifidobacterium species (165), the B. dentium genome only contains a limited assortment of mucin-related GH genes (GH2, GH42, GH29, and GH125). The majority of the B. dentium GH enzymes are predicted to utilize and convert various intracellular or target dietary compounds, such as cellobiose, xylose, ribose, arabinose, mannitol, and sorbitol (136). Interestingly, the glycosyl hydrolases harbored by B. dentium may be advantageous in early life. B. dentium is frequently isolated from healthy breast-fed infants (39, 84, 85, 166). Breast milk glycans commonly contain galactose residues (167), and B. dentium harbors the galactosidases GH2 and GH42. As a result, B. dentium may use milk glycans during postnatal human development to establish a niche.

Consistent with the larger repertoire of mucin-degrading glycosyl hydrolases, previous studies have shown that mucin-maintaining or mucin-degrading species, such as B. bifidum (PRL2010, D119, and L22), B. breve NCIMB8807, and B. longum NCIMB8809, can grow in the presence of mucin alone (72, 75, 168–170). Our data indicate that B. dentium does not harbor the same glycosyl hydrolase genes and is unable to grow in mucin alone. Under pathological conditions with a diminished gastrointestinal mucus layer, a relative preponderance of mucin builders versus mucin degraders may be beneficial. Mucin-building bifidobacteria that enhance mucin production without mucin-degrading abilities would be preferred under specific biological conditions. B. dentium has the distinct ability to upregulate MUC2 synthesis, influence host glycosylation patterns, and promote MUC2 secretion, coupled with the inability to degrade mammalian host mucins. Thus, we speculate that B. dentium may be beneficial in intestinal environments lacking sufficient mucin.

One caveat to our work is that several bifidobacterial species have been identified in dental caries (120, 171–181). These bifidobacteria include gut-associated strains, such as those of B. breve, B. adolescentis, B. longum, and our microbe of interest, B. dentium. It has been postulated that bifidobacteria exist as stable species in dental caries due to their adhesive properties and their resistance to acidity (173, 182, 183). However, the results of clinical studies assessing the effects of bifidobacteria on the oral microbiota are controversial. Currently, no studies have dissected the role of bifidobacteria in the pathogenesis of caries. Of note, studies have also shown that bifidobacteria, including B. dentium, inhibit the growth of Porphyromonas gingivalis in in vitro biofilm models (184), which may have a positive effect on subgingival biofilm and thereby may enhance gingival health. One theory, the specific plaque hypothesis, has proposed that only a few specific species, such as Streptococcus mutans and Streptococcus sobrinus, are actively involved in the disease (185). While it is possible that Bifidobacterium species may be indirectly contributing to caries via acid production, the role of bifidobacteria within these carries remains unclear. More studies are needed before it is possible to draw conclusions on bifidobacteria in dental caries.

B. dentium, similar to other Bifidobacterium strains, is a recognized member of the healthy infant and adult human gut microbiota, according to the Human Microbiome Project (86) and sequencing studies (39, 84, 85, 166). Our data indicate that B. dentium is a commensal bacterium of the intestine and harbors beneficial mucin-modulating properties. Collectively, these data point to the potential role of next-generation mucin-building probiotics, such as B. dentium, in rescuing intestinal mucus layer function and treating intestinal disorders in the future.

MATERIALS AND METHODS

Materials.The monosaccharides d-glucose and d-mannose were purchased from Sigma-Aldrich. l-Fucose, N-acetyl- d-glucosamine (GlcNAc), N-acetyl-d-galactosamine (GalNAc), and N-acetylneuraminic acid (Neu5Ac) were purchased from Carbosynth Limited. All other reagents were from Sigma-Aldrich, unless otherwise stated.

Bacteriology.Bifidobacterium dentium ATCC 27678 (adult human fecal isolate), Bifidobacterium longum subsp. infantis ATCC 15697 (infant intestinal isolate), Bifidobacterium longum subsp. longum ATCC 55813 (adult human fecal isolate), and Bifidobacterium breve ATCC 15698 (infant intestinal isolate) (ATCC, American Type Culture Collection) were cultured in an anaerobic workstation (Anaerobe Systems AS-580) in a mixture of 5% CO2, 5% H2, and 90% N2. Colonies were grown in de Man-Rogosa-Sharpe (MRS) medium (Difco) anaerobically at 37°C overnight. Single colonies were isolated from cultures plated on MRS agar plates. B. dentium was adjusted to optical density at 600 nm (OD600) of 0.1, subcultured into a fully defined medium termed lactic acid bacteria defined medium IV (LDMIV) (see Table S1 in the supplemental material), and incubated for up to 48 h anaerobically at 37°C. Bacterial growth was measured by the OD600 and CFU counts on MRS agar. For T84 cell treatment, B. dentium was grown overnight in MRS anaerobically at 37°C, and cells were pelleted by centrifugation at 5,000 × g for 5 min. Bacterial cells were washed three times with sterile anaerobic phosphate-buffered saline (PBS) to wash away residual MRS, and the bacterial pellet was resuspended in anaerobic optically clear FluoroBrite DMEM (catalog no. A1896701; Thermo Fisher) and incubated for 6 h. Following the incubation, cultures were centrifuged to remove bacteria, the pH was adjusted to 7, and the cultures were filtered through a 0.2-μm-pore-size polyvinylidene difluoride (PVDF) membrane (Millipore) to sterilize the supernatant, termed “conditioned medium.” For animal experiments, B. dentium was grown anaerobically in MRS to log-phase growth (1.6 × 109 cells ml−1). Bacterial viability was confirmed for each gavage session by serially plating B. dentium and assessing CFU via conventional plating on MRS agar.

TABLE S1

Recipe for the fully defined lactic acid bacteria defined medium IV. Download Table S1, PDF file, 0.10 MB.
Copyright © 2019 Engevik et al.

This content is distributed under the terms of the Creative Commons Attribution 4.0 International license.

Gnotobiotic mouse model.All experimental procedures and animal care were approved by the Institutional Animal Care and Use Committee (IACUC) at Baylor College of Medicine, Houston, TX. Swiss Webster germfree mice were purchased from Taconic and housed in the Baylor College of Medicine germfree facility. Mice were housed in filter-top cages in sterile isolators, and all food, water, and bedding were irradiated for sterility. Feces from experimental mice and isolator sentinels were collected at various time points and examined routinely for colonization by plating anaerobically and aerobically on blood agar. Male and female adult 7- to 9-month-old mice were housed under gnotobiotic (germfree) conditions. Germfree mice were monoassociated by oral gavage with 3.2 × 108 CFU ml−1 B. dentium ATCC 27678 grown in MRS (total, n = 33; males, n =16; females, n =17). Control germfree mice received sterile MRS gavages (total, n = 31; males, n = 14; females, n =17) or 3.2 × 108 CFU ml−1 heat-killed B. dentium (males, n = 5; females, n = 5). For heat-killed bacteria, B. dentium was heated at 60°C for 30 min. Culture viability was confirmed by plating on MRS agar.

Cultures were maintained in sterile Hungate tubes until administration to the mice to maintain anaerobic conditions. Mice received oral gavage doses once every other day for 1 week and one final gavage a week later. Fecal samples were plated on MRS and blood agar (Hardy Diagnostics) over time to monitor colonization. Plates were incubated anaerobically and aerobically at 37°C. To ensure that the germfree mice harbored no bacteria, gDNA was extracted from stool samples before the start of the experiment and at the time of euthanasia and examined by qPCR using a 16S rRNA gene-based universal bacterial probe for bacterial colonization. Weight was monitored over the course of treatment, and mice were euthanized 72 h after the last gavage.

Intestinal tissue staining.(i) Immunofluorescence. Mouse tissue segments were embedded in paraffin, and 7-μm sections were processed for staining. Following dehydration, slides were incubated for 20 min at 100°C in antigen unmasking solution citrate buffer pH 6 (Vector Labs) in a steamer for antigen retrieval. Sections were blocked for 1 h at room temperature in 10% donkey and/or goat serum. Staining was performed with an anti-MUC2 antibody (dilution 1:200, rabbit anti-MUC2, catalog no. sc-15334, Santa Cruz Biotechnology Inc.) and incubated overnight at 4°C. The primary antibody was recognized using donkey-anti-rabbit Alexa Fluor 488 antibody diluted at 1:300 (Life Technologies) and incubated for 1 h at room temperature. Hoechst 33342 (Invitrogen) was incubated at room temperature for 10 min to stain the nuclei. Coverslips were mounted with mounting medium (Life Technologies).

A panel of fluorescein isothiocyanate (FITC)-conjugated lectins were used to identify terminal mucin glycans. These lectins included Ulex europaeus agglutinin-1 (UEA-1; sugar recognized, fucose), concanavalin A agglutinin (CONA; mannose), Dolichos biflorus agglutinin (DBA; N-acetylgalactosamine), peanut agglutinin (PNA; galactose), wheat germ agglutinin (WGA; N-acetylglucosamine), and Sambucus nigra agglutinin (SNA; sialic acid) (catalog no. FLK-2100 [for UEA-1, CONA, DBA, PNA, WGA] and FL-1201 [for SNA]; Vector Laboratories), as previously described (5). Briefly, deparaffinized sections were blocked with PBS containing 10% bovine albumin (BSA) and stained with 10 μg/ml FITC-labeled lectin at room temperature for 1 h. Sections were washed three times in PBS and counterstained in Hoechst 33342. All slides were imaged on an upright wide-field epifluorescence Nikon Eclipse 90i microscope with the following objectives: 20× Plan Apo (numerical aperture [NA], 0.75) differential interference contrast (DIC) objective and a 40× Plan Apo (NA, 0.95) DIC objective. All fluorescent images were recorded using a CoolSNAP HQ2 camera (Photometrics) with a Spectra X light-emitting diode (LED) light source (Lumencor). Semiquantitative analysis of fluorescent stains was accomplished using Fiji (formerly known as ImageJ) software by tabulating the mean pixel intensity (National Institutes of Health) in five regions/per slide, at n = 11 to 12 mice/group, as previously described (4, 186, 187).

(ii) H&E, PAS-AB, and tissue Gram stain. Paraffin-embedded tissue sections were serially dehydrated in xylene and ethanol. Sections were stained with hematoxylin and eosin (H&E) for intestine architecture or periodic acid-Schiff–alcian blue (PAS-AB) to identify goblet cells and mucus. To identify bacterial colonization, sections were incubated with the following Gram staining reagents: crystal violet, Gram iodine, and safranin, with a series of washes with a decolorizer solvent, followed by picric acid-acetone. After alcohol and xylene dehydration steps, sections were coverslipped with Fluoromount aqueous mounting medium (Sigma-Aldrich catalog no. F4680) and imaged on an upright wide-field Nikon Eclipse 90i microscope. H&E and PAS-AB sections were recorded using a DS-Fi1-U2 camera (Nikon) with a 20× Plan Apo (NA, 0.75) DIC objective.

(iii) Fluorescence in situ hybridization staining. B. dentium localization was examined in mouse colon sections using the Bifidobacterium-specific FISH probe Bif164 (5′-CATCCGGCATTACCACCC-3′), and total bacteria were examined using the universal bacterial FISH probe EUB338 (5′-GCTGCCTCCCGTAGGAGT-3′) (Integrated DNA Technologies [IDT]). Briefly, 7-μm sections were dehydrated in ethanol and incubated with the Bifidobacterium probe at 45°C in a dark humidifying chamber. Slides were hybridized for 45 min and counterstained with Hoechst 33342 for 10 min at room temperature (Invitrogen). All slides were imaged on an upright wide-field epifluorescence Nikon Eclipse 90i microscope (Tokyo, Japan) with a 40× Plan Apo (NA, 0.95) DIC objective. FISH images were recorded using a CoolSNAP HQ2 camera (Photometrics) using a Nikon Intensilight C-HGFI mercury lamp.

Germfree mouse mucus isolation.Germfree mouse cecum contents were collected (n = 7) and pooled for mucus extraction. Mucus was prepared similarly to previously described methods (70, 91). Briefly, pooled cecum samples were diluted in four volumes of ice-cold phosphate-buffered saline containing EDTA, phenylmethylsulfonyl fluoride, and iodoacetamide. Particulate matter was removed by centrifugation, and mucin protein was isolated by precipitation with ice-cold ethanol. Precipitated mucin was lyophilized and purified by CsCl isopycnic density gradient centrifugation at a starting density of 1.39 g ml−1 using a 70 Ti rotor (Beckman Coulter, Inc.) (188, 189). Dialyzed mucins were lyophilized and resuspended in HEPES-buffered Hanks’ salt solution (HH) at a concentration of 1 mg/ml. Mucin concentration was ascertained by a bicinchoninic acid (BCA) assay with purified pig stomach mucin (Sigma-Aldrich) as a standard. For adhesion assays, 100 μl of mucus solution (1 mg/ml) was immobilized in 96-well polystyrene microtiter plates (Maxisorp, Nunc; VWR) by overnight incubation at 4°C, as previously described (70). Wells were washed 3× with 200 μl of HH prior to the addition of bacteria to remove unbound mucus.

Mucin adhesion assay.Bifidobacterium dentium ATCC 27678, Bifidobacterium infantis ATCC 15697, Bifidobacterium breve ATCC 15698, and Bifidobacterium longum ATCC 55813 were grown anaerobically in MRS. Bacterial suspensions were adjusted to an OD600 of 2 in PBS and fluorescently tagged by incubating with 10 μM carboxyfluorescein diacetate-succinimidyl ester (CFDA-SE; catalog no. C1157; Thermo Fisher) for 30 min at 37°C anaerobically, similar to previous bacterial staining reports (190, 191). Fluorescent bacteria were washed 3 times with anaerobic PBS and resuspended in PBS at an OD600 of 2. To determine bacterial adhesion, 100 μl of labeled bacteria was added to the microtiter plates coated with germfree mouse mucus and 2-fold serially diluted in PBS. Following a 1-h incubation at 37°C, the wells were washed 3 times with 200 μl of HH to remove unattached bacteria. Bacterial adherence was examined by reading fluorescence (excitation/emission, 492/517 nm) in a microtiter plate reader (Synergy H1; Biotek), and the presence of bacteria was confirmed by microscopy. The results from the adhesion assay are presented as means from four replicates in three independent experiments.

T84 culturing and treatment.(i) T84 cell culturing. Human colon-derived T84 (ATCC CCL-248) cells were obtained from the ATCC. Cells were regularly maintained in a complete growth medium (CGM) of Gibco Dulbecco's modified Eagle medium F-12 (Thermo Fisher) supplemented with 2 mM GlutaMAX (Thermo Fisher) and 10% fetal bovine serum (FBS). Cultures were maintained in a humidified atmosphere at 37°C and 5% CO2. Cells were routinely tested for Mycoplasma contamination using the Mycoplasma detection kit (catalog no. LT07-518; Lonza). For an examination of Muc2 mRNA levels, cells were seeded at 5 × 104 cells/cm2 in 12-well tissue culture-treated plates (Corning) until the cells reached confluence. Cells were then treated with various concentrations of B. dentium FluoroBrite conditioned DMEM, heat-killed B. dentium bacteria, γ-aminobutyric acid (GABA), or 5 mM sodium acetate overnight in DMEM without glucose and without FBS. Following incubation (16 to 18 h), cells were treated with TRIzol reagent for RNA extraction.

(ii) T84 mucin expulsion assays. T84 cells were seeded at 5 × 104 cells/cm2 into a 24-well plate and incubated at 37°C and 5% CO2 until the cells reached confluence. Cells were then serum starved overnight and treated with various amounts of B. dentium FluoroBrite conditioned DMEM, GABA, or acetate diluted in FluoroBrite DMEM with 1× GlutaMAX (no FBS). To inhibit autophagy, cells were pretreated for 1 h with the PI3K inhibitor 3-methyladenine (3-MA; Sigma-Aldrich catalog no. M9281). As positive and negative controls, cells were treated with 10 μM the calcium ionophore A21387, a known stimulator of mucus (124), or 25 μM BAPTA, a Ca2+ chelator which is known to inhibit mucus production (192, 193). Supernatant (100 μl) was collected at 1, 3, and 24 h and incubated with alcian blue, as previously described (194). Briefly, the supernatant was incubated with an equal volume of 1% alcian blue and 3% glacial acetic acid for 2 h at room temperature. Mucins were pelleted by centrifugation at 12,000 × g for 10 min, and pellets were washed three times with PBS. Following washes, mucin pellets were resuspended in PBS containing 10% SDS and sonicated to release the alcian blue color. Absorbance was measured at 620 nm on a spectrophotometer. As an alternative method for analyzing mucus release, confluent T84 monolayers in 96-well plates were thoroughly washed with PBS and incubated with 10 μM CFDA-SE in PBS for 30 min at 37°C and 5% CO2 to fluorescently tag all proteins. Following the incubation, cells were washed three times in PBS and incubated in FluoroBrite DMEM for 3 h at 37°C and 5% CO2 to allow the CFDA-SE to incorporate into all proteins. Cells were then treated with B. dentium FluoroBrite conditioned DMEM, GABA, acetate, 3-MA, A21387, or BAPTA, as described above. Supernatants (100 μl) were collected at 1 h and examined by fluorescent plate reader at an excitation/emission of 492/517 nm.

(iii) Generation of T84 GCaMP6S cells for live-cell calcium imaging. For calcium (Ca2+) imaging studies, T84 cells were cultured in 12-well plates to 50 to 60% confluence and transduced using lentivirus pLVX-GCaMP6s with 10 μg/ml Polybrene (catalog no. TR-1003-G; Millipore) in CGM and incubated for 48 h. The lentivirus construct and packaging were previously described (195). Two days after transduction, cells were cultured in the presence of puromycin (10 μg/ml) to select for stably expressing cells. For Ca2+ measurements, T84 GCaMP6s were grown to confluence on 8-well chamber slides (Matek) and then changed to an optically clear FluoroBrite DMEM (Invitrogen) supplemented with 15 mM HEPES (Invitrogen), 1× sodium pyruvate (Invitrogen), 1× GlutaMAX (Invitrogen), and 1× nonessential amino acids (Invitrogen). B. dentium FluoroBrite conditioned DMEM was added in uninoculated FluoroBrite DMEM (50% final concentration). Cells were placed in an Okolabs stage-top incubation chamber with CO2 mixing and humidity control and placed on an Nikon TiE inverted wide-field epifluorescence microscope with a motorized X, Y, and Z stage for software-controlled multiposition imaging. Cells were imaged with wide-field epifluorescence using a 20× PlanFluor (NA, 0.45) phase-contrast objective or a 20× Plan Apo (NA, 0.75) differential interference contrast objective, using a Spectra X LED light source (Lumencor). Images were recorded using an ORCA-Flash 4.0 scientific complementary metal-oxide semiconductor (sCMOS) camera (Hamamatsu), and the Nikon Elements v4.5 software was used for data acquisition and image analysis. Following the experiment, cell viability was examined by staining cells with 3 μM calcein AM (live-cell dye, catalog no. C3099; Invitrogen) and 2.5 μM propidium iodide (dead-cell dye, catalog no. P4170; Sigma-Aldrich).

Scanning electron microscopy.The MUC2-producing human colonic carcinoma cell line LS174T ATCC CL-188 (ATCC) was grown in DMEM supplemented with 10% fetal bovine serum at 37°C and 5% CO2. Approximately 1 × 105 cells were seeded onto Corning Costar 24-well culture plates containing poly-l-lysine-coated coverslips and grown to confluence. B. dentium was incubated with confluent coverslips at 2 × 105 bacteria and incubated for 1 h anaerobically at 37°C. Coverslips were then washed thoroughly with PBS (3 times) and fixed in 2.5% glutaraldehyde in PBS for 1 h at room temperature. Coverslips were dehydrated with ethanol and coated in 20 nm of gold using a desktop sputtering system (Denton Desk II). Slides were viewed in a scanning electron microscope (FEI XL-30FEG) at 12 kV.

Quantitative real-time PCR.A stool sample was collected to examine bacterial composition, and genomic DNA was isolated using the Zymo gDNA MiniPrep kit (catalog no. 11-317C; Zymo Research) with bead beating. Mouse colon cells were stored in TRIzol reagent, and RNA was extracted according to the manufacturer’s details. The SensiFAST cDNA synthesis kit (Bioline USA, Inc.) was used to synthesize cDNA from 1 μg RNA. cDNA was examined by quantitative real-time PCR (qPCR) via Fast SYBR green (Thermo Fisher) and primers (Table 1) using a QuantStudio 3 qPCR machine (Applied Biosystems). All reactions were carried out in 96-well plates with melting curves to ensure primer specificity. Relative mRNA levels were examined using the ΔΔCT method with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene, generating fold changes for each gene.

View this table:
  • View inline
  • View popup
TABLE 1

Primer sequences for real-time PCR using SYBR green chemistry

Statistical analysis.Graphs were generated using the GraphPad Prism software (version 6; GraphPad, Inc.). For statistical analysis, comparisons were made with either one-way analysis of variance (ANOVA) with the Holm-Sidak post hoc test or with a t test using SigmaPlot. The data are presented as mean ± standard deviation, with differences between the groups considered significant at a P value of <0.05.

FOOTNOTES

    • Received 1 May 2019
    • Accepted 11 May 2019
    • Published 18 June 2019
  • Copyright © 2019 Engevik et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Johansson ME
    . 2014. Mucus layers in inflammatory bowel disease. Inflamm Bowel Dis 20:2124–2131. doi:10.1097/MIB.0000000000000117.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Johansson ME,
    2. Phillipson M,
    3. Petersson J,
    4. Velcich A,
    5. Holm L,
    6. Hansson GC
    . 2008. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105:15064–15069. doi:10.1073/pnas.0803124105.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Johansson ME,
    2. Sjovall H,
    3. Hansson GC
    . 2013. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 10:352–361. doi:10.1038/nrgastro.2013.35.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Engevik MA,
    2. Aihara E,
    3. Montrose MH,
    4. Shull GE,
    5. Hassett DJ,
    6. Worrell RT
    . 2013. Loss of NHE3 alters gut microbiota composition and influences Bacteroides thetaiotaomicron growth. Am J Physiol Gastrointest Liver Physiol 305:G697–G711. doi:10.1152/ajpgi.00184.2013.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Engevik MA,
    2. Hickerson A,
    3. Shull GE,
    4. Worrell RT
    . 2013. Acidic conditions in the NHE2−/− mouse intestine result in an altered mucosa-associated bacterial population with changes in mucus oligosaccharides. Cell Physiol Biochem 32:111–128. doi:10.1159/000356632.
    OpenUrlCrossRef
  6. 6.↵
    1. Jensen PH,
    2. Kolarich D,
    3. Packer NH
    . 2010. Mucin-type O-glycosylation–putting the pieces together. FEBS J 277:81–94. doi:10.1111/j.1742-4658.2009.07429.x.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Crost EH,
    2. Tailford LE,
    3. Le Gall G,
    4. Fons M,
    5. Henrissat B,
    6. Juge N
    . 2013. Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent. PLoS One 8:e76341. doi:10.1371/journal.pone.0076341.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Larsson JM,
    2. Karlsson H,
    3. Sjovall H,
    4. Hansson GC
    . 2009. A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. Glycobiology 19:756–766. doi:10.1093/glycob/cwp048.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Swidsinski A,
    2. Loening-Baucke V,
    3. Theissig F,
    4. Engelhardt H,
    5. Bengmark S,
    6. Koch S,
    7. Lochs H,
    8. Dörffel Y
    . 2007. Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut 56:343–350. doi:10.1136/gut.2006.098160.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Tytgat KM,
    2. van der Wal JW,
    3. Einerhand AW,
    4. Büller HA,
    5. Dekker J
    . 1996. Quantitative analysis of MUC2 synthesis in ulcerative colitis. Biochem Biophys Res Commun 224:397–405. doi:10.1006/bbrc.1996.1039.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Podolsky DK,
    2. Fournier DA
    . 1988. Alterations in mucosal content of colonic glycoconjugates in inflammatory bowel disease defined by monoclonal antibodies. Gastroenterology 95:379–387. doi:10.1016/0016-5085(88)90494-5.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Fu J,
    2. Wei B,
    3. Wen T,
    4. Johansson ME,
    5. Liu X,
    6. Bradford E,
    7. Thomsson KA,
    8. McGee S,
    9. Mansour L,
    10. Tong M,
    11. McDaniel JM,
    12. Sferra TJ,
    13. Turner JR,
    14. Chen H,
    15. Hansson GC,
    16. Braun J,
    17. Xia L
    . 2011. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest 121:1657–1666. doi:10.1172/JCI45538.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Larsson JM,
    2. Karlsson H,
    3. Crespo JG,
    4. Johansson ME,
    5. Eklund L,
    6. Sjovall H,
    7. Hansson GC
    . 2011. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis 17:2299–2307. doi:10.1002/ibd.21625.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Bergstrom KS,
    2. Xia L
    . 2013. Mucin-type O-glycans and their roles in intestinal homeostasis. Glycobiology 23:1026–1037. doi:10.1093/glycob/cwt045.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Schwerbrock NM,
    2. Makkink MK,
    3. van der Sluis M,
    4. Buller HA,
    5. Einerhand AW,
    6. Sartor RB,
    7. Dekker J
    . 2004. Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. Inflamm Bowel Dis 10:811–823. doi:10.1097/00054725-200411000-00016.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Velcich A,
    2. Yang W,
    3. Heyer J,
    4. Fragale A,
    5. Nicholas C,
    6. Viani S,
    7. Kucherlapati R,
    8. Lipkin M,
    9. Yang K,
    10. Augenlicht L
    . 2002. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295:1726–1729. doi:10.1126/science.1069094.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Van der Sluis M,
    2. De Koning BAE,
    3. De Bruijn ACJM,
    4. Velcich A,
    5. Meijerink JPP,
    6. Van Goudoever JB,
    7. Büller HA,
    8. Dekker J,
    9. Van Seuningen I,
    10. Renes IB,
    11. Einerhand AWC
    . 2006. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131:117–129. doi:10.1053/j.gastro.2006.04.020.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Heazlewood CK,
    2. Cook MC,
    3. Eri R,
    4. Price GR,
    5. Tauro SB,
    6. Taupin D,
    7. Thornton DJ,
    8. Png CW,
    9. Crockford TL,
    10. Cornall RJ,
    11. Adams R,
    12. Kato M,
    13. Nelms KA,
    14. Hong NA,
    15. Florin TH,
    16. Goodnow CC,
    17. McGuckin MA
    . 2008. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 5:e54. doi:10.1371/journal.pmed.0050054.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. McGuckin MA,
    2. Eri RD,
    3. Das I,
    4. Lourie R,
    5. Florin TH
    . 2011. Intestinal secretory cell ER stress and inflammation. Biochem Soc Trans 39:1081–1085. doi:10.1042/BST0391081.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Park SW,
    2. Zhen G,
    3. Verhaeghe C,
    4. Nakagami Y,
    5. Nguyenvu LT,
    6. Barczak AJ,
    7. Killeen N,
    8. Erle DJ
    . 2009. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc Natl Acad Sci U S A 106:6950–6955. doi:10.1073/pnas.0808722106.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Bergstrom K,
    2. Fu J,
    3. Johansson ME,
    4. Liu X,
    5. Gao N,
    6. Wu Q,
    7. Song J,
    8. McDaniel JM,
    9. McGee S,
    10. Chen W,
    11. Braun J,
    12. Hansson GC,
    13. Xia L
    . 2017. Core 1- and 3-derived O-glycans collectively maintain the colonic mucus barrier and protect against spontaneous colitis in mice. Mucosal Immunol 10:91–103. doi:10.1038/mi.2016.45.
    OpenUrlCrossRef
  22. 22.↵
    1. Whelan K,
    2. Quigley EM
    . 2013. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29:184–189. doi:10.1097/MOG.0b013e32835d7bba.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Sun J,
    2. Shen X,
    3. Li Y,
    4. Guo Z,
    5. Zhu W,
    6. Zuo L,
    7. Zhao J,
    8. Gu L,
    9. Gong J,
    10. Li J
    . 2016. Therapeutic potential to modify the mucus barrier in inflammatory bowel disease. Nutrients 8:E44. doi:10.3390/nu8010044.
    OpenUrlCrossRef
  24. 24.↵
    1. Schroeder BO,
    2. Birchenough GMH,
    3. Stahlman M,
    4. Arike L,
    5. Johansson MEV,
    6. Hansson GC,
    7. Backhed F
    . 2018. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe 23:27–40.e7. doi:10.1016/j.chom.2017.11.004.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Gomi A,
    2. Harima-Mizusawa N,
    3. Shibahara-Sone H,
    4. Kano M,
    5. Miyazaki K,
    6. Ishikawa F
    . 2013. Effect of Bifidobacterium bifidum BF-1 on gastric protection and mucin production in an acute gastric injury rat model. J Dairy Sci 96:832–837. doi:10.3168/jds.2012-5950.
    OpenUrlCrossRef
  26. 26.↵
    1. Javed NH,
    2. Alsahly MB,
    3. Khubchandani J
    . 2016. Oral feeding of probiotic Bifidobacterium infantis: colonic morphological changes in rat model of TNBS-induced colitis. Scientifica (Cairo) 2016:9572596. doi:10.1155/2016/9572596.
    OpenUrlCrossRef
  27. 27.↵
    1. Kawahara T,
    2. Makizaki Y,
    3. Oikawa Y,
    4. Tanaka Y,
    5. Maeda A,
    6. Shimakawa M,
    7. Komoto S,
    8. Moriguchi K,
    9. Ohno H,
    10. Taniguchi K
    . 2017. Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors. PLoS One 12:e0173979. doi:10.1371/journal.pone.0173979.
    OpenUrlCrossRef
  28. 28.↵
    1. Khailova L,
    2. Dvorak K,
    3. Arganbright KM,
    4. Halpern MD,
    5. Kinouchi T,
    6. Yajima M,
    7. Dvorak B
    . 2009. Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 297:G940–G949. doi:10.1152/ajpgi.00141.2009.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Venturi A,
    2. Gionchetti P,
    3. Rizzello F,
    4. Johansson R,
    5. Zucconi E,
    6. Brigidi P,
    7. Matteuzzi D,
    8. Campieri M
    . 1999. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 13:1103–1108. doi:10.1046/j.1365-2036.1999.00560.x.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Gionchetti P,
    2. Rizzello F,
    3. Venturi A,
    4. Campieri M
    . 2000. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 15:489–493. doi:10.1046/j.1440-1746.2000.02162.x.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Yatsunenko T,
    2. Rey FE,
    3. Manary MJ,
    4. Trehan I,
    5. Dominguez-Bello MG,
    6. Contreras M,
    7. Magris M,
    8. Hidalgo G,
    9. Baldassano RN,
    10. Anokhin AP,
    11. Heath AC,
    12. Warner B,
    13. Reeder J,
    14. Kuczynski J,
    15. Caporaso JG,
    16. Lozupone CA,
    17. Lauber C,
    18. Clemente JC,
    19. Knights D,
    20. Knight R,
    21. Gordon JI
    . 2012. Human gut microbiome viewed across age and geography. Nature 486:222–227. doi:10.1038/nature11053.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Bäckhed F,
    2. Roswall J,
    3. Peng Y,
    4. Feng Q,
    5. Jia H,
    6. Kovatcheva-Datchary P,
    7. Li Y,
    8. Xia Y,
    9. Xie H,
    10. Zhong H,
    11. Khan MT,
    12. Zhang J,
    13. Li J,
    14. Xiao L,
    15. Al-Aama J,
    16. Zhang D,
    17. Lee YS,
    18. Kotowska D,
    19. Colding C,
    20. Tremaroli V,
    21. Yin Y,
    22. Bergman S,
    23. Xu X,
    24. Madsen L,
    25. Kristiansen K,
    26. Dahlgren J,
    27. Wang J
    . 2015. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17:852. doi:10.1016/j.chom.2015.05.012.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Walker AW,
    2. Martin JC,
    3. Scott P,
    4. Parkhill J,
    5. Flint HJ,
    6. Scott KP
    . 2015. 16S rRNA gene-based profiling of the human infant gut microbiota is strongly influenced by sample processing and PCR primer choice. Microbiome 3:26. doi:10.1186/s40168-015-0087-4.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Fernández L,
    2. Langa S,
    3. Martin V,
    4. Maldonado A,
    5. Jimenez E,
    6. Martin R,
    7. Rodriguez JM
    . 2013. The human milk microbiota: origin and potential roles in health and disease. Pharmacol Res 69:1–10. doi:10.1016/j.phrs.2012.09.001.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Jost T,
    2. Lacroix C,
    3. Braegger C,
    4. Chassard C
    . 2015. Impact of human milk bacteria and oligosaccharides on neonatal gut microbiota establishment and gut health. Nutr Rev 73:426–437. doi:10.1093/nutrit/nuu016.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Roger LC,
    2. Costabile A,
    3. Holland DT,
    4. Hoyles L,
    5. McCartney AL
    . 2010. Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 156:3329–3341. doi:10.1099/mic.0.043224-0.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Koenig JE,
    2. Spor A,
    3. Scalfone N,
    4. Fricker AD,
    5. Stombaugh J,
    6. Knight R,
    7. Angenent LT,
    8. Ley RE
    . 2011. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 108(Suppl 1):4578–4585. doi:10.1073/pnas.1000081107.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Harmsen HJ,
    2. Wildeboer-Veloo AC,
    3. Raangs GC,
    4. Wagendorp AA,
    5. Klijn N,
    6. Bindels JG,
    7. Welling GW
    . 2000. Analysis of intestinal flora development in breast-fed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr 30:61–67. doi:10.1097/00005176-200001000-00019.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Turroni F,
    2. Peano C,
    3. Pass DA,
    4. Foroni E,
    5. Severgnini M,
    6. Claesson MJ,
    7. Kerr C,
    8. Hourihane J,
    9. Murray D,
    10. Fuligni F,
    11. Gueimonde M,
    12. Margolles A,
    13. De Bellis G,
    14. O'Toole PW,
    15. van Sinderen D,
    16. Marchesi JR,
    17. Ventura M
    . 2012. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 7:e36957. doi:10.1371/journal.pone.0036957.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Eckburg PB,
    2. Bik EM,
    3. Bernstein CN,
    4. Purdom E,
    5. Dethlefsen L,
    6. Sargent M,
    7. Gill SR,
    8. Nelson KE,
    9. Relman DA
    . 2005. Diversity of the human intestinal microbial flora. Science 308:1635–1638. doi:10.1126/science.1110591.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Mueller S,
    2. Saunier K,
    3. Hanisch C,
    4. Norin E,
    5. Alm L,
    6. Midtvedt T,
    7. Cresci A,
    8. Silvi S,
    9. Orpianesi C,
    10. Verdenelli MC,
    11. Clavel T,
    12. Koebnick C,
    13. Zunft HJ,
    14. Dore J,
    15. Blaut M
    . 2006. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study. Appl Environ Microbiol 72:1027–1033. doi:10.1128/AEM.72.2.1027-1033.2006.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Saavedra JM,
    2. Bauman NA,
    3. Oung I,
    4. Perman JA,
    5. Yolken RH
    . 1994. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 344:1046–1049. doi:10.1016/S0140-6736(94)91708-6.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Bernet MF,
    2. Brassart D,
    3. Neeser JR,
    4. Servin AL
    . 1993. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 59:4121–4128.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Fukuda S,
    2. Toh H,
    3. Hase K,
    4. Oshima K,
    5. Nakanishi Y,
    6. Yoshimura K,
    7. Tobe T,
    8. Clarke JM,
    9. Topping DL,
    10. Suzuki T,
    11. Taylor TD,
    12. Itoh K,
    13. Kikuchi J,
    14. Morita H,
    15. Hattori M,
    16. Ohno H
    . 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–547. doi:10.1038/nature09646.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Fukuda S,
    2. Toh H,
    3. Taylor TD,
    4. Ohno H,
    5. Hattori M
    . 2012. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes 3:449–454. doi:10.4161/gmic.21214.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Sekine K,
    2. Toida T,
    3. Saito M,
    4. Kuboyama M,
    5. Kawashima T,
    6. Hashimoto Y
    . 1985. A new morphologically characterized cell wall preparation (whole peptidoglycan) from Bifidobacterium infantis with a higher efficacy on the regression of an established tumor in mice. Cancer Res 45:1300–1307.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Rowland IR,
    2. Rumney CJ,
    3. Coutts JT,
    4. Lievense LC
    . 1998. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 19:281–285. doi:10.1093/carcin/19.2.281.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Le Leu RK,
    2. Hu Y,
    3. Brown IL,
    4. Woodman RJ,
    5. Young GP
    . 2010. Synbiotic intervention of Bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. Carcinogenesis 31:246–251. doi:10.1093/carcin/bgp197.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Tavan E,
    2. Cayuela C,
    3. Antoine JM,
    4. Cassand P
    . 2002. Antimutagenic activities of various lactic acid bacteria against food mutagens: heterocyclic amines. J Dairy Res 69:335–341. doi:10.1017/S002202990200540X.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Pool-Zobel BL,
    2. Neudecker C,
    3. Domizlaff I,
    4. Ji S,
    5. Schillinger U,
    6. Rumney C,
    7. Moretti M,
    8. Vilarini I,
    9. Scassellati-Sforzolini R,
    10. Rowland I
    . 1996. Lactobacillus- and Bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer 26:365–380. doi:10.1080/01635589609514492.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Chenoll E,
    2. Rivero M,
    3. Codoner FM,
    4. Martinez-Blanch JF,
    5. Ramon D,
    6. Genoves S,
    7. Moreno Munoz JA
    . 2015. Complete genome sequence of Bifidobacterium longum subsp. infantis strain CECT 7210, a probiotic strain active against rotavirus infections. Genome Announc 3:e00105-15. doi:10.1128/genomeA.000105-15.
    OpenUrlCrossRef
  52. 52.↵
    1. Patole SK,
    2. Rao SC,
    3. Keil AD,
    4. Nathan EA,
    5. Doherty DA,
    6. Simmer KN
    . 2016. Benefits of Bifidobacterium breve M-16V supplementation in preterm neonates–a retrospective cohort study. PLoS One 11:e0150775. doi:10.1371/journal.pone.0150775.
    OpenUrlCrossRef
  53. 53.↵
    1. Veereman-Wauters G,
    2. Staelens S,
    3. Van de Broek H,
    4. Plaskie K,
    5. Wesling F,
    6. Roger LC,
    7. McCartney AL,
    8. Assam P
    . 2011. Physiological and bifidogenic effects of prebiotic supplements in infant formulae. J Pediatr Gastroenterol Nutr 52:763–771. doi:10.1097/MPG.0b013e3182139f39.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Marteau P,
    2. Cuillerier E,
    3. Meance S,
    4. Gerhardt MF,
    5. Myara A,
    6. Bouvier M,
    7. Bouley C,
    8. Tondu F,
    9. Bommelaer G,
    10. Grimaud JC
    . 2002. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 16:587–593. doi:10.1046/j.1365-2036.2002.01188.x.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Andrade S,
    2. Borges N
    . 2009. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J Dairy Res 76:469–474. doi:10.1017/S0022029909990173.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Guyonnet D,
    2. Chassany O,
    3. Ducrotte P,
    4. Picard C,
    5. Mouret M,
    6. Mercier CH,
    7. Matuchansky C
    . 2007. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26:475–486. doi:10.1111/j.1365-2036.2007.03362.x.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Yang YX,
    2. He M,
    3. Hu G,
    4. Wei J,
    5. Pages P,
    6. Yang XH,
    7. Bourdu-Naturel S
    . 2008. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 14:6237–6243. doi:10.3748/wjg.14.6237.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    1. Kleessen B,
    2. Sykura B,
    3. Zunft HJ,
    4. Blaut M
    . 1997. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 65:1397–1402. doi:10.1093/ajcn/65.5.1397.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Duffy LC,
    2. Zielezny MA,
    3. Riepenhoff-Talty M,
    4. Dryja D,
    5. Sayahtaheri-Altaie S,
    6. Griffiths E,
    7. Ruffin D,
    8. Barrett H,
    9. Ogra PL
    . 1994. Reduction of virus shedding by B. bifidum in experimentally induced MRV infection. Dig Dis Sci 39:2334–2340. doi:10.1007/BF02087647.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Duffy LC,
    2. Zielezny MA,
    3. Riepenhoff-Talty M,
    4. Dryja D,
    5. Sayahtaheri-Altaie S,
    6. Griffiths E,
    7. Ruffin D,
    8. Barrett H,
    9. Rossman J,
    10. Ogra PL
    . 1993. Effectiveness of Bifidobacterium bifidum in experimentally induced MRV infection: dietary implications in formulas for newborns. Endocr Regul 27:223–229.
    OpenUrlPubMed
  61. 61.↵
    1. Perdigon G,
    2. Alvarez S,
    3. Rachid M,
    4. Aguero G,
    5. Gobbato N
    . 1995. Immune system stimulation by probiotics. J Dairy Sci 78:1597–1606. doi:10.3168/jds.S0022-0302(95)76784-4.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    1. Picard C,
    2. Fioramonti J,
    3. Francois A,
    4. Robinson T,
    5. Neant F,
    6. Matuchansky C
    . 2005. Review article: bifidobacteria as probiotic agents–physiological effects and clinical benefits. Aliment Pharmacol Ther 22:495–512. doi:10.1111/j.1365-2036.2005.02615.x.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Gueimonde M,
    2. Margolles A,
    3. de los Reyes-Gavilán CG,
    4. Salminen S
    . 2007. Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bile–a preliminary study. Int J Food Microbiol 113:228–232. doi:10.1016/j.ijfoodmicro.2006.05.017.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Cronin M,
    2. Ventura M,
    3. Fitzgerald GF,
    4. van Sinderen D
    . 2011. Progress in genomics, metabolism and biotechnology of bifidobacteria. Int J Food Microbiol 149:4–18. doi:10.1016/j.ijfoodmicro.2011.01.019.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. O’Callaghan A,
    2. van Sinderen D
    . 2016. Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 7:925. doi:10.3389/fmicb.2016.00925.
    OpenUrlCrossRef
  66. 66.↵
    1. González-Rodriguez I,
    2. Sanchez B,
    3. Ruiz L,
    4. Turroni F,
    5. Ventura M,
    6. Ruas-Madiedo P,
    7. Gueimonde M,
    8. Margolles A
    . 2012. Role of extracellular transaldolase from Bifidobacterium bifidum in mucin adhesion and aggregation. Appl Environ Microbiol 78:3992–3998. doi:10.1128/AEM.08024-11.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. He F,
    2. Ouwehan AC,
    3. Hashimoto H,
    4. Isolauri E,
    5. Benno Y,
    6. Salminen S
    . 2001. Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol Immunol 45:259–262. doi:10.1111/j.1348-0421.2001.tb02615.x.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Izquierdo E,
    2. Medina M,
    3. Ennahar S,
    4. Marchioni E,
    5. Sanz Y
    . 2008. Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains. Curr Microbiol 56:613–618. doi:10.1007/s00284-008-9135-7.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Kirjavainen PV,
    2. Ouwehand AC,
    3. Isolauri E,
    4. Salminen SJ
    . 1998. The ability of probiotic bacteria to bind to human intestinal mucus. FEMS Microbiol Lett 167:185–189. doi:10.1111/j.1574-6968.1998.tb13226.x.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    1. Juntunen M,
    2. Kirjavainen PV,
    3. Ouwehand AC,
    4. Salminen SJ,
    5. Isolauri E
    . 2001. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 8:293–296. doi:10.1128/CDLI.8.2.293-296.2001.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    1. Tailford LE,
    2. Crost EH,
    3. Kavanaugh D,
    4. Juge N
    . 2015. Mucin glycan foraging in the human gut microbiome. Front Genet 6:81. doi:10.3389/fgene.2015.00081.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Ruas-Madiedo P,
    2. Gueimonde M,
    3. Fernández-García M,
    4. de los Reyes-Gavilán CG,
    5. Margolles A
    . 2008. Mucin degradation by Bifidobacterium strains isolated from the human intestinal microbiota. Appl Environ Microbiol 74:1936–1940. doi:10.1128/AEM.02509-07.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Turroni F,
    2. Bottacini F,
    3. Foroni E,
    4. Mulder I,
    5. Kim JH,
    6. Zomer A,
    7. Sanchez B,
    8. Bidossi A,
    9. Ferrarini A,
    10. Giubellini V,
    11. Delledonne M,
    12. Henrissat B,
    13. Coutinho P,
    14. Oggioni M,
    15. Fitzgerald GF,
    16. Mills D,
    17. Margolles A,
    18. Kelly D,
    19. van Sinderen D,
    20. Ventura M
    . 2010. Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. Proc Natl Acad Sci U S A 107:19514–19519. doi:10.1073/pnas.1011100107.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Crociani F,
    2. Alessandrini A,
    3. Mucci MM,
    4. Biavati B
    . 1994. Degradation of complex carbohydrates by Bifidobacterium spp. Int J Food Microbiol 24:199–210. doi:10.1016/0168-1605(94)90119-8.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    1. Salyers AA,
    2. West SE,
    3. Vercellotti JR,
    4. Wilkins TD
    . 1977. Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol 34:529–533.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Ruiz L,
    2. Gueimonde M,
    3. Couté Y,
    4. Salminen S,
    5. Sanchez J-C,
    6. de los Reyes-Gavilán CG,
    7. Margolles A
    . 2011. Evaluation of the ability of Bifidobacterium longum to metabolize human intestinal mucus. FEMS Microbiol Lett 314:125–130. doi:10.1111/j.1574-6968.2010.02159.x.
    OpenUrlCrossRefPubMedWeb of Science
  77. 77.↵
    1. Pudlo NA,
    2. Urs K,
    3. Kumar SS,
    4. German JB,
    5. Mills DA,
    6. Martens EC
    . 2015. Symbiotic human gut bacteria with variable metabolic priorities for host mucosal glycans. mBio 6:e01282-15. doi:10.1128/mBio.01282-15.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Miller RS,
    2. Hoskins LC
    . 1981. Mucin degradation in human colon ecosystems. Fecal population densities of mucin-degrading bacteria estimated by a “most probable number” method. Gastroenterology 81:759–765. doi:10.1016/0016-5085(81)90503-5.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Hoskins LC,
    2. Agustines M,
    3. McKee WB,
    4. Boulding ET,
    5. Kriaris M,
    6. Niedermeyer G
    . 1985. Mucin degradation in human colon ecosystems. Isolation and properties of fecal strains that degrade ABH blood group antigens and oligosaccharides from mucin glycoproteins. J Clin Invest 75:944–953. doi:10.1172/JCI111795.
    OpenUrlCrossRefPubMedWeb of Science
  80. 80.↵
    1. Lozupone CA,
    2. Hamady M,
    3. Cantarel BL,
    4. Coutinho PM,
    5. Henrissat B,
    6. Gordon JI,
    7. Knight R
    . 2008. The convergence of carbohydrate active gene repertoires in human gut microbes. Proc Natl Acad Sci U S A 105:15076–15081. doi:10.1073/pnas.0807339105.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    1. Turroni F,
    2. Strati F,
    3. Foroni E,
    4. Serafini F,
    5. Duranti S,
    6. van Sinderen D,
    7. Ventura M
    . 2012. Analysis of predicted carbohydrate transport systems encoded by Bifidobacterium bifidum PRL2010. Appl Environ Microbiol 78:5002–5012. doi:10.1128/AEM.00629-12.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    1. Turroni F,
    2. Foroni E,
    3. Pizzetti P,
    4. Giubellini V,
    5. Ribbera A,
    6. Merusi P,
    7. Cagnasso P,
    8. Bizzarri B,
    9. de'Angelis GL,
    10. Shanahan F,
    11. van Sinderen D,
    12. Ventura M
    . 2009. Exploring the diversity of the bifidobacterial population in the human intestinal tract. Appl Environ Microbiol 75:1534–1545. doi:10.1128/AEM.02216-08.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Favier CF,
    2. de Vos WM,
    3. Akkermans AD
    . 2003. Development of bacterial and bifidobacterial communities in feces of newborn babies. Anaerobe 9:219–229. doi:10.1016/j.anaerobe.2003.07.001.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    1. He M,
    2. Li M,
    3. Wang SY,
    4. Zhang LL,
    5. Miao JJ,
    6. Shi L,
    7. Yu Q,
    8. Yao JR,
    9. Huang CY,
    10. He F
    . 2016. Analyzing colonization of bifidobacteria in infants with real-time fluorescent quantitative PCR. Sichuan Da Xue Xue Bao Yi Xue Ban 47:527–532. (In Chinese.)
    OpenUrl
  85. 85.↵
    1. Nagpal R,
    2. Kurakawa T,
    3. Tsuji H,
    4. Takahashi T,
    5. Kawashima K,
    6. Nagata S,
    7. Nomoto K,
    8. Yamashiro Y
    . 2017. Evolution of gut Bifidobacterium population in healthy Japanese infants over the first three years of life: a quantitative assessment. Sci Rep 7:10097. doi:10.1038/s41598-017-10711-5.
    OpenUrlCrossRef
  86. 86.↵
    Human Microbiome Project Consortium. 2012. Structure, function and diversity of the healthy human microbiome. Nature 486:207–214. doi:10.1038/nature11234.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.↵
    1. Pokusaeva K,
    2. Johnson C,
    3. Luk B,
    4. Uribe G,
    5. Fu Y,
    6. Oezguen N,
    7. Matsunami RK,
    8. Lugo M,
    9. Major A,
    10. Mori-Akiyama Y,
    11. Hollister EB,
    12. Dann SM,
    13. Shi XZ,
    14. Engler DA,
    15. Savidge T,
    16. Versalovic J
    . 2017. GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. Neurogastroenterol Motil 29:e12904. doi:10.1111/nmo.12904.
    OpenUrlCrossRef
  88. 88.↵
    1. Nebra Y,
    2. Bonjoch X,
    3. Blanch AR
    . 2003. Use of Bifidobacterium dentium as an indicator of the origin of fecal water pollution. Appl Environ Microbiol 69:2651–2656. doi:10.1128/aem.69.5.2651-2656.2003.
    OpenUrlAbstract/FREE Full Text
  89. 89.↵
    1. Ménard O,
    2. Butel MJ,
    3. Gaboriau-Routhiau V,
    4. Waligora-Dupriet AJ
    . 2008. Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated from infants. Appl Environ Microbiol 74:660–666. doi:10.1128/AEM.01261-07.
    OpenUrlAbstract/FREE Full Text
  90. 90.↵
    1. Ventura M,
    2. Elli M,
    3. Reniero R,
    4. Zink R
    . 2001. Molecular microbial analysis of Bifidobacterium isolates from different environments by the species-specific amplified ribosomal DNA restriction analysis (ARDRA). FEMS Microbiol Ecol 36:113–121. doi:10.1111/j.1574-6941.2001.tb00831.x.
    OpenUrlCrossRefPubMedWeb of Science
  91. 91.↵
    1. Ouwehand AC,
    2. Isolauri E,
    3. Kirjavainen PV,
    4. Salminen SJ
    . 1999. Adhesion of four Bifidobacterium strains to human intestinal mucus from subjects in different age groups. FEMS Microbiol Lett 172:61–64. doi:10.1111/j.1574-6968.1999.tb13450.x.
    OpenUrlCrossRefPubMedWeb of Science
  92. 92.↵
    1. Nishiyama K,
    2. Kawanabe A,
    3. Miyauchi H,
    4. Abe F,
    5. Tsubokawa D,
    6. Ishihara K,
    7. Yamamoto Y,
    8. Mukai T
    . 2014. Evaluation of bifidobacterial adhesion to acidic sugar chains of porcine colonic mucins. Biosci Biotechnol Biochem 78:1444–1451. doi:10.1080/09168451.2014.918491.
    OpenUrlCrossRef
  93. 93.↵
    1. Li H,
    2. Limenitakis JP,
    3. Fuhrer T,
    4. Geuking MB,
    5. Lawson MA,
    6. Wyss M,
    7. Brugiroux S,
    8. Keller I,
    9. Macpherson JA,
    10. Rupp S,
    11. Stolp B,
    12. Stein JV,
    13. Stecher B,
    14. Sauer U,
    15. McCoy KD,
    16. Macpherson AJ
    . 2015. The outer mucus layer hosts a distinct intestinal microbial niche. Nat Commun 6:8292. doi:10.1038/ncomms9292.
    OpenUrlCrossRefPubMed
  94. 94.↵
    1. Kiyohara M,
    2. Nakatomi T,
    3. Kurihara S,
    4. Fushinobu S,
    5. Suzuki H,
    6. Tanaka T,
    7. Shoda S,
    8. Kitaoka M,
    9. Katayama T,
    10. Yamamoto K,
    11. Ashida H
    . 2012. α-N-Acetylgalactosaminidase from infant-associated bifidobacteria belonging to novel glycoside hydrolase family 129 is implicated in alternative mucin degradation pathway. J Biol Chem 287:693–700. doi:10.1074/jbc.M111.277384.
    OpenUrlAbstract/FREE Full Text
  95. 95.↵
    1. Suzuki R,
    2. Katayama T,
    3. Kitaoka M,
    4. Kumagai H,
    5. Wakagi T,
    6. Shoun H,
    7. Ashida H,
    8. Yamamoto K,
    9. Fushinobu S
    . 2009. Crystallographic and mutational analyses of substrate recognition of endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum. J Biochem 146:389–398. doi:10.1093/jb/mvp086.
    OpenUrlCrossRefPubMedWeb of Science
  96. 96.↵
    1. Fujita K,
    2. Sakaguchi T,
    3. Sakamoto A,
    4. Shimokawa M,
    5. Kitahara K
    . 2014. Bifidobacterium longum subsp. longum exo-β-1,3-galactanase, an enzyme for the degradation of type II arabinogalactan. Appl Environ Microbiol 80:4577–4584. doi:10.1128/AEM.00802-14.
    OpenUrlAbstract/FREE Full Text
  97. 97.↵
    1. Fujita K,
    2. Oura F,
    3. Nagamine N,
    4. Katayama T,
    5. Hiratake J,
    6. Sakata K,
    7. Kumagai H,
    8. Yamamoto K
    . 2005. Identification and molecular cloning of a novel glycoside hydrolase family of core 1 type O-glycan-specific endo-alpha-N-acetylgalactosaminidase from Bifidobacterium longum. J Biol Chem 280:37415–37422. doi:10.1074/jbc.M506874200.
    OpenUrlAbstract/FREE Full Text
  98. 98.↵
    1. Sato M,
    2. Liebschner D,
    3. Yamada Y,
    4. Matsugaki N,
    5. Arakawa T,
    6. Wills SS,
    7. Hattie M,
    8. Stubbs KA,
    9. Ito T,
    10. Senda T,
    11. Ashida H,
    12. Fushinobu S
    . 2017. The first crystal structure of a family 129 glycoside hydrolase from a probiotic bacterium reveals critical residues and metal cofactors. J Biol Chem 292:12126–12138. doi:10.1074/jbc.M117.777391.
    OpenUrlAbstract/FREE Full Text
  99. 99.↵
    1. Grover M,
    2. Kashyap PC
    . 2014. Germ-free mice as a model to study effect of gut microbiota on host physiology. Neurogastroenterol Motil 26:745–748. doi:10.1111/nmo.12366.
    OpenUrlCrossRef
  100. 100.↵
    1. Wostmann BS,
    2. Larkin C,
    3. Moriarty A,
    4. Bruckner-Kardoss E
    . 1983. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci 33:46–50.
    OpenUrlPubMedWeb of Science
  101. 101.↵
    1. Rosenbaum M,
    2. Knight R,
    3. Leibel RL
    . 2015. The gut microbiota in human energy homeostasis and obesity. Trends Endocrinol Metab 26:493–501. doi:10.1016/j.tem.2015.07.002.
    OpenUrlCrossRefPubMed
  102. 102.↵
    1. Loesche WJ
    . 1969. Effect of bacterial contamination on cecal size and cecal contents of gnotobiotic rodents. J Bacteriol 99:520–526.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Enss ML,
    2. Grosse-Siestrup H,
    3. Schmidt-Wittig U,
    4. Gärtner K
    . 1992. Changes in colonic mucins of germfree rats in response to the introduction of a “normal” rat microbial flora. Rat colonic mucin. J Exp Anim Sci 35:110–119.
    OpenUrlPubMed
  104. 104.↵
    1. Derrien M,
    2. van Passel MW,
    3. van de Bovenkamp JH,
    4. Schipper RG,
    5. de Vos WM,
    6. Dekker J
    . 2010. Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 1:254–268. doi:10.4161/gmic.1.4.12778.
    OpenUrlCrossRefPubMed
  105. 105.↵
    1. Lindstedt G,
    2. Lindstedt S,
    3. Gustafsson BE
    . 1965. Mucus in intestinal contents of germfree rats. J Exp Med 121:201–213. doi:10.1084/jem.121.2.201.
    OpenUrlAbstract
  106. 106.↵
    1. Katz JP,
    2. Perreault N,
    3. Goldstein BG,
    4. Lee CS,
    5. Labosky PA,
    6. Yang VW,
    7. Kaestner KH
    . 2002. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129:2619–2628.
    OpenUrlAbstract/FREE Full Text
  107. 107.↵
    1. Morampudi V,
    2. Dalwadi U,
    3. Bhinder G,
    4. Sham HP,
    5. Gill SK,
    6. Chan J,
    7. Bergstrom KS,
    8. Huang T,
    9. Ma C,
    10. Jacobson K,
    11. Gibson DL,
    12. Vallance BA
    . 2016. The goblet cell-derived mediator RELM-beta drives spontaneous colitis in Muc2-deficient mice by promoting commensal microbial dysbiosis. Mucosal Immunol 9:1218–1233. doi:10.1038/mi.2015.140.
    OpenUrlCrossRef
  108. 108.↵
    1. Waddell A,
    2. Vallance JE,
    3. Moore PD,
    4. Hummel AT,
    5. Wu D,
    6. Shanmukhappa SK,
    7. Fei L,
    8. Washington MK,
    9. Minar P,
    10. Coburn LA,
    11. Nakae S,
    12. Wilson KT,
    13. Denson LA,
    14. Hogan SP,
    15. Rosen MJ
    . 2015. IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function. Inflamm Bowel Dis 21:2737–2746. doi:10.1097/MIB.0000000000000532.
    OpenUrlCrossRef
  109. 109.↵
    1. Turner JE,
    2. Stockinger B,
    3. Helmby H
    . 2013. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog 9:e1003698. doi:10.1371/journal.ppat.1003698.
    OpenUrlCrossRefPubMed
  110. 110.↵
    1. Sugimoto K,
    2. Ogawa A,
    3. Mizoguchi E,
    4. Shimomura Y,
    5. Andoh A,
    6. Bhan AK,
    7. Blumberg RS,
    8. Xavier RJ,
    9. Mizoguchi A
    . 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118:534–544. doi:10.1172/JCI33194.
    OpenUrlCrossRefPubMedWeb of Science
  111. 111.↵
    1. Seo DH,
    2. Che X,
    3. Kwak MS,
    4. Kim S,
    5. Kim JH,
    6. Ma HW,
    7. Kim DH,
    8. Kim TI,
    9. Kim WH,
    10. Kim SW,
    11. Cheon JH
    . 2017. Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease. Sci Rep 7:851. doi:10.1038/s41598-017-00840-2.
    OpenUrlCrossRef
  112. 112.↵
    1. Bry L,
    2. Falk PG,
    3. Midtvedt T,
    4. Gordon JI
    . 1996. A model of host-microbial interactions in an open mammalian ecosystem. Science 273:1380–1383. doi:10.1126/science.273.5280.1380.
    OpenUrlAbstract
  113. 113.↵
    1. Hooper LV,
    2. Midtvedt T,
    3. Gordon JI
    . 2002. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 22:283–307. doi:10.1146/annurev.nutr.22.011602.092259.
    OpenUrlCrossRefPubMedWeb of Science
  114. 114.↵
    1. Gouyer V,
    2. Dubuquoy L,
    3. Robbe-Masselot C,
    4. Neut C,
    5. Singer E,
    6. Plet S,
    7. Geboes K,
    8. Desreumaux P,
    9. Gottrand F,
    10. Desseyn JL
    . 2015. Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. Sci Rep 5:9577. doi:10.1038/srep09577.
    OpenUrlCrossRefPubMed
  115. 115.↵
    1. Johansson MEV,
    2. Jakobsson HE,
    3. Holmén-Larsson J,
    4. Schütte A,
    5. Ermund A,
    6. Rodríguez-Piñeiro AM,
    7. Arike L,
    8. Wising C,
    9. Svensson F,
    10. Bäckhed F,
    11. Hansson GC
    . 2015. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 18:582–592. doi:10.1016/j.chom.2015.10.007.
    OpenUrlCrossRefPubMed
  116. 116.↵
    1. Graziani F,
    2. Pujol A,
    3. Nicoletti C,
    4. Dou S,
    5. Maresca M,
    6. Giardina T,
    7. Fons M,
    8. Perrier J
    . 2016. Ruminococcus gnavus E1 modulates mucin expression and intestinal glycosylation. J Appl Microbiol 120:1403–1417. doi:10.1111/jam.13095.
    OpenUrlCrossRef
  117. 117.↵
    1. Arike L,
    2. Holmen-Larsson J,
    3. Hansson GC
    . 2017. Intestinal Muc2 mucin O-glycosylation is affected by microbiota and regulated by differential expression of glycosyltranferases. Glycobiology 27:318–328. doi:10.1093/glycob/cww134.
    OpenUrlCrossRefPubMed
  118. 118.↵
    1. Robinson LS,
    2. Lewis WG,
    3. Lewis AL
    . 2017. The sialate O-acetylesterase EstA from gut Bacteroidetes species enables sialidase-mediated cross-species foraging of 9-O-acetylated sialoglycans. J Biol Chem 292:11861–11872. doi:10.1074/jbc.M116.769232.
    OpenUrlAbstract/FREE Full Text
  119. 119.↵
    1. Neuberger A,
    2. Ratcliffe WA
    . 1972. The acid and enzymic hydrolysis of O-acetylated sialic acid residues from rabbit Tamm-Horsfall glycoprotein. Biochem J 129:683–693. doi:10.1042/bj1290683.
    OpenUrlAbstract/FREE Full Text
  120. 120.↵
    1. Ventura M,
    2. Turroni F,
    3. Zomer A,
    4. Foroni E,
    5. Giubellini V,
    6. Bottacini F,
    7. Canchaya C,
    8. Claesson MJ,
    9. He F,
    10. Mantzourani M,
    11. Mulas L,
    12. Ferrarini A,
    13. Gao B,
    14. Delledonne M,
    15. Henrissat B,
    16. Coutinho P,
    17. Oggioni M,
    18. Gupta RS,
    19. Zhang Z,
    20. Beighton D,
    21. Fitzgerald GF,
    22. O’Toole PW,
    23. van Sinderen D
    . 2009. The Bifidobacterium dentium Bd1 genome sequence reflects its genetic adaptation to the human oral cavity. PLoS Genet 5:e1000785. doi:10.1371/journal.pgen.1000785.
    OpenUrlCrossRefPubMed
  121. 121.↵
    1. Willemsen LE,
    2. Koetsier MA,
    3. van Deventer SJ,
    4. van Tol EA
    . 2003. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 52:1442–1447. doi:10.1136/gut.52.10.1442.
    OpenUrlAbstract/FREE Full Text
  122. 122.↵
    1. Burger-van Paassen N,
    2. Vincent A,
    3. Puiman PJ,
    4. van der Sluis M,
    5. Bouma J,
    6. Boehm G,
    7. van Goudoever JB,
    8. van Seuningen I,
    9. Renes IB
    . 2009. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 420:211–219. doi:10.1042/BJ20082222.
    OpenUrlAbstract/FREE Full Text
  123. 123.↵
    1. Hasnain SZ,
    2. Thornton DJ,
    3. Grencis RK
    . 2011. Changes in the mucosal barrier during acute and chronic Trichuris muris infection. Parasite Immunol 33:45–55. doi:10.1111/j.1365-3024.2010.01258.x.
    OpenUrlCrossRefPubMed
  124. 124.↵
    1. McCool DJ,
    2. Marcon MA,
    3. Forstner JF,
    4. Forstner GG
    . 1990. The T84 human colonic adenocarcinoma cell line produces mucin in culture and releases it in response to various secretagogues. Biochem J 267:491–500. doi:10.1042/bj2670491.
    OpenUrlAbstract/FREE Full Text
  125. 125.↵
    1. Cutting GR,
    2. Lu L,
    3. O'Hara BF,
    4. Kasch LM,
    5. Montrose-Rafizadeh C,
    6. Donovan DM,
    7. Shimada S,
    8. Antonarakis SE,
    9. Guggino WB,
    10. Uhl GR
    . 1991. Cloning of the gamma-aminobutyric acid (GABA) rho 1 cDNA: a GABA receptor subunit highly expressed in the retina. Proc Natl Acad Sci U S A 88:2673–2677. doi:10.1073/pnas.88.7.2673.
    OpenUrlAbstract/FREE Full Text
  126. 126.↵
    1. Garret M,
    2. Bascles L,
    3. Boue-Grabot E,
    4. Sartor P,
    5. Charron G,
    6. Bloch B,
    7. Margolskee RF
    . 1997. An mRNA encoding a putative GABA-gated chloride channel is expressed in the human cardiac conduction system. J Neurochem 68:1382–1389.
    OpenUrlPubMedWeb of Science
  127. 127.↵
    1. D’Souza WN,
    2. Douangpanya J,
    3. Mu S,
    4. Jaeckel P,
    5. Zhang M,
    6. Maxwell JR,
    7. Rottman JB,
    8. Labitzke K,
    9. Willee A,
    10. Beckmann H,
    11. Wang Y,
    12. Li Y,
    13. Schwandner R,
    14. Johnston JA,
    15. Towne JE,
    16. Hsu H
    . 2017. Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses. PLoS One 12:e0180190. doi:10.1371/journal.pone.0180190.
    OpenUrlCrossRef
  128. 128.↵
    1. Patel KK,
    2. Miyoshi H,
    3. Beatty WL,
    4. Head RD,
    5. Malvin NP,
    6. Cadwell K,
    7. Guan JL,
    8. Saitoh T,
    9. Akira S,
    10. Seglen PO,
    11. Dinauer MC,
    12. Virgin HW,
    13. Stappenbeck TS
    . 2013. Autophagy proteins control goblet cell function by potentiating reactive oxygen species production. EMBO J 32:3130–3144. doi:10.1038/emboj.2013.233.
    OpenUrlCrossRef
  129. 129.↵
    1. Abdullah LH,
    2. Bundy JT,
    3. Ehre C,
    4. Davis CW
    . 2003. Mucin secretion and PKC isoforms in SPOC1 goblet cells: differential activation by purinergic agonist and PMA. Am J Physiol Lung Cell Mol Physiol 285:L149–L160. doi:10.1152/ajplung.00359.2002.
    OpenUrlCrossRefPubMedWeb of Science
  130. 130.↵
    1. Ehre C,
    2. Rossi AH,
    3. Abdullah LH,
    4. De Pestel K,
    5. Hill S,
    6. Olsen JC,
    7. Davis CW
    . 2005. Barrier role of actin filaments in regulated mucin secretion from airway goblet cells. Am J Physiol Cell Physiol 288:C46–C56. doi:10.1152/ajpcell.00397.2004.
    OpenUrlCrossRef
  131. 131.↵
    1. Wollman R,
    2. Meyer T
    . 2012. Coordinated oscillations in cortical actin and Ca2+ correlate with cycles of vesicle secretion. Nat Cell Biol 14:1261–1269. doi:10.1038/ncb2614.
    OpenUrlCrossRefPubMedWeb of Science
  132. 132.↵
    1. Chen TW,
    2. Wardill TJ,
    3. Sun Y,
    4. Pulver SR,
    5. Renninger SL,
    6. Baohan A,
    7. Schreiter ER,
    8. Kerr RA,
    9. Orger MB,
    10. Jayaraman V,
    11. Looger LL,
    12. Svoboda K,
    13. Kim DS
    . 2013. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499:295–300. doi:10.1038/nature12354.
    OpenUrlCrossRefPubMedWeb of Science
  133. 133.↵
    1. Niemann HH,
    2. Schubert WD,
    3. Heinz DW
    . 2004. Adhesins and invasins of pathogenic bacteria: a structural view. Microbes Infect 6:101–112. doi:10.1016/j.micinf.2003.11.001.
    OpenUrlCrossRefPubMedWeb of Science
  134. 134.↵
    1. Collado MC,
    2. Gueimonde M,
    3. Hernandez M,
    4. Sanz Y,
    5. Salminen S
    . 2005. Adhesion of selected Bifidobacterium strains to human intestinal mucus and the role of adhesion in enteropathogen exclusion. J Food Prot 68:2672–2678. doi:10.4315/0362-028X-68.12.2672.
    OpenUrlCrossRefPubMedWeb of Science
  135. 135.↵
    1. Serafini F,
    2. Strati F,
    3. Ruas-Madiedo P,
    4. Turroni F,
    5. Foroni E,
    6. Duranti S,
    7. Milano F,
    8. Perotti A,
    9. Viappiani A,
    10. Guglielmetti S,
    11. Buschini A,
    12. Margolles A,
    13. van Sinderen D,
    14. Ventura M
    . 2013. Evaluation of adhesion properties and antibacterial activities of the infant gut commensal Bifidobacterium bifidum PRL2010. Anaerobe 21:9–17. doi:10.1016/j.anaerobe.2013.03.003.
    OpenUrlCrossRefPubMedWeb of Science
  136. 136.↵
    1. Lee JH,
    2. O’Sullivan DJ
    . 2010. Genomic insights into bifidobacteria. Microbiol Mol Biol Rev 74:378–416. doi:10.1128/MMBR.00004-10.
    OpenUrlAbstract/FREE Full Text
  137. 137.↵
    1. Marillier RG,
    2. Michels C,
    3. Smith EM,
    4. Fick LC,
    5. Leeto M,
    6. Dewals B,
    7. Horsnell WG,
    8. Brombacher F
    . 2008. IL-4/IL-13 independent goblet cell hyperplasia in experimental helminth infections. BMC Immunol 9:11. doi:10.1186/1471-2172-9-11.
    OpenUrlCrossRefPubMed
  138. 138.↵
    1. Oeser K,
    2. Schwartz C,
    3. Voehringer D
    . 2015. Conditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths. Mucosal Immunol 8:672–682. doi:10.1038/mi.2014.101.
    OpenUrlCrossRefPubMed
  139. 139.↵
    1. Finkelman FD,
    2. Shea-Donohue T,
    3. Morris SC,
    4. Gildea L,
    5. Strait R,
    6. Madden KB,
    7. Schopf L,
    8. Urban JF, Jr..
    2004. Interleukin-4- and interleukin-13-mediated host protection against intestinal nematode parasites. Immunol Rev 201:139–155. doi:10.1111/j.0105-2896.2004.00192.x.
    OpenUrlCrossRefPubMedWeb of Science
  140. 140.↵
    1. Tukler Henriksson J,
    2. Coursey TG,
    3. Corry DB,
    4. De Paiva CS,
    5. Pflugfelder SC
    . 2015. IL-13 stimulates proliferation and expression of mucin and immunomodulatory genes in cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci 56:4186–4197. doi:10.1167/iovs.14-15496.
    OpenUrlCrossRef
  141. 141.↵
    1. Lemjabbar H,
    2. Basbaum C
    . 2002. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 8:41–46. doi:10.1038/nm0102-41.
    OpenUrlCrossRefPubMedWeb of Science
  142. 142.↵
    1. Knoop KA,
    2. McDonald KG,
    3. McCrate S,
    4. McDole JR,
    5. Newberry RD
    . 2015. Microbial sensing by goblet cells controls immune surveillance of luminal antigens in the colon. Mucosal Immunol 8:198–210. doi:10.1038/mi.2014.58.
    OpenUrlCrossRefPubMed
  143. 143.↵
    1. Wlodarska M,
    2. Thaiss CA,
    3. Nowarski R,
    4. Henao-Mejia J,
    5. Zhang JP,
    6. Brown EM,
    7. Frankel G,
    8. Levy M,
    9. Katz MN,
    10. Philbrick WM,
    11. Elinav E,
    12. Finlay BB,
    13. Flavell RA
    . 2014. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156:1045–1059. doi:10.1016/j.cell.2014.01.026.
    OpenUrlCrossRefPubMedWeb of Science
  144. 144.↵
    1. Birchenough GM,
    2. Johansson ME,
    3. Gustafsson JK,
    4. Bergstrom JH,
    5. Hansson GC
    . 2015. New developments in goblet cell mucus secretion and function. Mucosal Immunol 8:712–719. doi:10.1038/mi.2015.32.
    OpenUrlCrossRefPubMed
  145. 145.↵
    1. Delgado MA,
    2. Deretic V
    . 2009. Toll-like receptors in control of immunological autophagy. Cell Death Differ 16:976–983. doi:10.1038/cdd.2009.40.
    OpenUrlCrossRefPubMedWeb of Science
  146. 146.↵
    1. Delgado MA,
    2. Elmaoued RA,
    3. Davis AS,
    4. Kyei G,
    5. Deretic V
    . 2008. Toll-like receptors control autophagy. EMBO J 27:1110–1121. doi:10.1038/emboj.2008.31.
    OpenUrlCrossRefPubMedWeb of Science
  147. 147.↵
    1. van Bergenhenegouwen J,
    2. Kraneveld AD,
    3. Rutten L,
    4. Kettelarij N,
    5. Garssen J,
    6. Vos AP
    . 2014. Extracellular vesicles modulate host-microbe responses by altering TLR2 activity and phagocytosis. PLoS One 9:e89121. doi:10.1371/journal.pone.0089121.
    OpenUrlCrossRef
  148. 148.↵
    1. Teitelbaum JE,
    2. Walker WA
    . 2002. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr 22:107–138. doi:10.1146/annurev.nutr.22.110901.145412.
    OpenUrlCrossRefPubMedWeb of Science
  149. 149.↵
    1. Wong JM,
    2. de Souza R,
    3. Kendall CW,
    4. Emam A,
    5. Jenkins DJ
    . 2006. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40:235–243. doi:10.1097/00004836-200603000-00015.
    OpenUrlCrossRefPubMedWeb of Science
  150. 150.↵
    1. Ambort D,
    2. Johansson ME,
    3. Gustafsson JK,
    4. Nilsson HE,
    5. Ermund A,
    6. Johansson BR,
    7. Koeck PJ,
    8. Hebert H,
    9. Hansson GC
    . 2012. Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin. Proc Natl Acad Sci U S A 109:5645–5650. doi:10.1073/pnas.1120269109.
    OpenUrlAbstract/FREE Full Text
  151. 151.↵
    1. Moore BA,
    2. Sharkey KA,
    3. Mantle M
    . 1996. Role of 5-HT in cholera toxin-induced mucin secretion in the rat small intestine. Am J Physiol 270:G1001–G1009. doi:10.1152/ajpgi.1996.270.6.G1001.
    OpenUrlCrossRefPubMedWeb of Science
  152. 152.↵
    1. Plaisancié P,
    2. Barcelo A,
    3. Moro F,
    4. Claustre J,
    5. Chayvialle JA,
    6. Cuber JC
    . 1998. Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 275:G1073–G1084. doi:10.1152/ajpgi.1998.275.5.G1073.
    OpenUrlCrossRefPubMedWeb of Science
  153. 153.↵
    1. Spohn SN,
    2. Bianco F,
    3. Scott RB,
    4. Keenan CM,
    5. Linton AA,
    6. O'Neill CH,
    7. Bonora E,
    8. Dicay M,
    9. Lavoie B,
    10. Wilcox RL,
    11. MacNaughton WK,
    12. De Giorgio R,
    13. Sharkey KA,
    14. Mawe GM
    . 2016. Protective actions of epithelial 5-hydroxytryptamine 4 receptors in normal and inflamed colon. Gastroenterology 151:933–944.e3. doi:10.1053/j.gastro.2016.07.032.
    OpenUrlCrossRefPubMed
  154. 154.↵
    1. Hoffman JM,
    2. Tyler K,
    3. MacEachern SJ,
    4. Balemba OB,
    5. Johnson AC,
    6. Brooks EM,
    7. Zhao H,
    8. Swain GM,
    9. Moses PL,
    10. Galligan JJ,
    11. Sharkey KA,
    12. Greenwood-Van Meerveld B,
    13. Mawe GM
    . 2012. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142:844–854.e4. doi:10.1053/j.gastro.2011.12.041.
    OpenUrlCrossRefPubMedWeb of Science
  155. 155.↵
    1. Yan F,
    2. Cao H,
    3. Cover TL,
    4. Whitehead R,
    5. Washington MK,
    6. Polk DB
    . 2007. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132:562–575. doi:10.1053/j.gastro.2006.11.022.
    OpenUrlCrossRefPubMedWeb of Science
  156. 156.↵
    1. Halm DR,
    2. Halm ST
    . 1999. Secretagogue response of goblet cells and columnar cells in human colonic crypts. Am J Physiol 277:C501–C522. doi:10.1152/ajpcell.1999.277.3.C501.
    OpenUrlCrossRefPubMed
  157. 157.↵
    1. Gustafsson JK,
    2. Ermund A,
    3. Johansson ME,
    4. Schutte A,
    5. Hansson GC,
    6. Sjovall H
    . 2012. An ex vivo method for studying mucus formation, properties, and thickness in human colonic biopsies and mouse small and large intestinal explants. Am J Physiol Gastrointest Liver Physiol 302:G430–G438. doi:10.1152/ajpgi.00405.2011.
    OpenUrlCrossRefPubMedWeb of Science
  158. 158.↵
    1. Ermund A,
    2. Schutte A,
    3. Johansson ME,
    4. Gustafsson JK,
    5. Hansson GC
    . 2013. Studies of mucus in mouse stomach, small intestine, and colon. I. Gastrointestinal mucus layers have different properties depending on location as well as over the Peyer’s patches. Am J Physiol Gastrointest Liver Physiol 305:G341–G347. doi:10.1152/ajpgi.00046.2013.
    OpenUrlCrossRefPubMedWeb of Science
  159. 159.↵
    1. Neutra MR,
    2. O'Malley LJ,
    3. Specian RD
    . 1982. Regulation of intestinal goblet cell secretion. II. A survey of potential secretagogues. Am J Physiol 242:G380–G387. doi:10.1152/ajpgi.1982.242.4.G380.
    OpenUrlCrossRefPubMed
  160. 160.↵
    1. Specian RD,
    2. Neutra MR
    . 1980. Mechanism of rapid mucus secretion in goblet cells stimulated by acetylcholine. J Cell Biol 85:626–640. doi:10.1083/jcb.85.3.626.
    OpenUrlAbstract/FREE Full Text
  161. 161.↵
    1. Tsuboi K,
    2. Nishitani M,
    3. Takakura A,
    4. Imai Y,
    5. Komatsu M,
    6. Kawashima H
    . 2015. Autophagy protects against colitis by the maintenance of normal gut microflora and secretion of mucus. J Biol Chem 290:20511–20526. doi:10.1074/jbc.M114.632257.
    OpenUrlAbstract/FREE Full Text
  162. 162.↵
    1. Krimi RB,
    2. Kotelevets L,
    3. Dubuquoy L,
    4. Plaisancie P,
    5. Walker F,
    6. Lehy T,
    7. Desreumaux P,
    8. Van Seuningen I,
    9. Chastre E,
    10. Forgue-Lafitte ME,
    11. Marie JC
    . 2008. Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm Bowel Dis 14:931–941. doi:10.1002/ibd.20420.
    OpenUrlCrossRefPubMedWeb of Science
  163. 163.↵
    1. Subramani DB,
    2. Johansson ME,
    3. Dahlen G,
    4. Hansson GC
    . 2010. Lactobacillus and Bifidobacterium species do not secrete protease that cleaves the MUC2 mucin which organises the colon mucus. Benef Microbes 1:343–350. doi:10.3920/BM2010.0039.
    OpenUrlCrossRefPubMedWeb of Science
  164. 164.↵
    1. Milani C,
    2. Lugli GA,
    3. Duranti S,
    4. Turroni F,
    5. Bottacini F,
    6. Mangifesta M,
    7. Sanchez B,
    8. Viappiani A,
    9. Mancabelli L,
    10. Taminiau B,
    11. Delcenserie V,
    12. Barrangou R,
    13. Margolles A,
    14. van Sinderen D,
    15. Ventura M
    . 2014. Genomic encyclopedia of type strains of the genus Bifidobacterium. Appl Environ Microbiol 80:6290–6302. doi:10.1128/AEM.02308-14.
    OpenUrlAbstract/FREE Full Text
  165. 165.↵
    1. Milani C,
    2. Lugli GA,
    3. Duranti S,
    4. Turroni F,
    5. Mancabelli L,
    6. Ferrario C,
    7. Mangifesta M,
    8. Hevia A,
    9. Viappiani A,
    10. Scholz M,
    11. Arioli S,
    12. Sanchez B,
    13. Lane J,
    14. Ward DV,
    15. Hickey R,
    16. Mora D,
    17. Segata N,
    18. Margolles A,
    19. van Sinderen D,
    20. Ventura M
    . 2015. Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut. Sci Rep 5:15782. doi:10.1038/srep15782.
    OpenUrlCrossRefPubMed
  166. 166.↵
    1. Rinne MM,
    2. Gueimonde M,
    3. Kalliomaki M,
    4. Hoppu U,
    5. Salminen SJ,
    6. Isolauri E
    . 2005. Similar bifidogenic effects of prebiotic-supplemented partially hydrolyzed infant formula and breastfeeding on infant gut microbiota. FEMS Immunol Med Microbiol 43:59–65. doi:10.1016/j.femsim.2004.07.005.
    OpenUrlCrossRefPubMed
  167. 167.↵
    1. Kirmiz N,
    2. Robinson RC,
    3. Shah IM,
    4. Barile D,
    5. Mills DA
    . 2018. Milk glycans and their interaction with the infant-gut microbiota. Annu Rev Food Sci Technol 9:429–450. doi:10.1146/annurev-food-030216-030207.
    OpenUrlCrossRef
  168. 168.↵
    1. Bayliss CE,
    2. Houston AP
    . 1984. Characterization of plant polysaccharide- and mucin-fermenting anaerobic bacteria from human feces. Appl Environ Microbiol 48:626–632.
    OpenUrlAbstract/FREE Full Text
  169. 169.↵
    1. Abe F,
    2. Muto M,
    3. Yaeshima T,
    4. Iwatsuki K,
    5. Aihara H,
    6. Ohashi Y,
    7. Fujisawa T
    . 2010. Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. Anaerobe 16:131–136. doi:10.1016/j.anaerobe.2009.07.006.
    OpenUrlCrossRef
  170. 170.↵
    1. Egan M,
    2. Motherway MO,
    3. Kilcoyne M,
    4. Kane M,
    5. Joshi L,
    6. Ventura M,
    7. van Sinderen D
    . 2014. Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in a mucin-based medium. BMC Microbiol 14:282. doi:10.1186/s12866-014-0282-7.
    OpenUrlCrossRefPubMed
  171. 171.↵
    1. Becker MR,
    2. Paster BJ,
    3. Leys EJ,
    4. Moeschberger ML,
    5. Kenyon SG,
    6. Galvin JL,
    7. Boches SK,
    8. Dewhirst FE,
    9. Griffen AL
    . 2002. Molecular analysis of bacterial species associated with childhood caries. J Clin Microbiol 40:1001–1009. doi:10.1128/jcm.40.3.1001-1009.2002.
    OpenUrlAbstract/FREE Full Text
  172. 172.↵
    1. Eriksson L,
    2. Lif Holgerson P,
    3. Johansson I
    . 2017. Saliva and tooth biofilm bacterial microbiota in adolescents in a low caries community. Sci Rep 7:5861. doi:10.1038/s41598-017-06221-z.
    OpenUrlCrossRef
  173. 173.↵
    1. Nakajo K,
    2. Takahashi N,
    3. Beighton D
    . 2010. Resistance to acidic environments of caries-associated bacteria: Bifidobacterium dentium and Bifidobacterium longum. Caries Res 44:431–437. doi:10.1159/000318582.
    OpenUrlCrossRefPubMedWeb of Science
  174. 174.↵
    1. Crociani F,
    2. Biavati B,
    3. Alessandrini A,
    4. Chiarini C,
    5. Scardovi V
    . 1996. Bifidobacterium inopinatum sp. nov. and Bifidobacterium denticolens sp. nov., two new species isolated from human dental caries. Int J Syst Bacteriol 46:564–571. doi:10.1099/00207713-46-2-564.
    OpenUrlCrossRefPubMed
  175. 175.↵
    1. Modesto M,
    2. Biavati B,
    3. Mattarelli P
    . 2006. Occurrence of the family bifidobacteriaceae in human dental caries and plaque. Caries Res 40:271–276. doi:10.1159/000092237.
    OpenUrlCrossRefPubMed
  176. 176.↵
    1. Hojo K,
    2. Nagaoka S,
    3. Murata S,
    4. Taketomo N,
    5. Ohshima T,
    6. Maeda N
    . 2007. Reduction of vitamin K concentration by salivary Bifidobacterium strains and their possible nutritional competition with Porphyromonas gingivalis. J Appl Microbiol 103:1969–1974. doi:10.1111/j.1365-2672.2007.03436.x.
    OpenUrlCrossRefPubMed
  177. 177.↵
    1. Edwardsson S
    . 1974. Bacteriological studies on deep areas of carious dentine. Odontol Revy Suppl 32:1–143.
    OpenUrlPubMed
  178. 178.↵
    1. Sanyal B,
    2. Russell C
    . 1978. Nonsporing, anaerobic, Gram-positive rods in saliva and the gingival crevice of humans. Appl Environ Microbiol 35:670–678.
    OpenUrlAbstract/FREE Full Text
  179. 179.↵
    1. Maeda N
    . 1980. Anaerobic, Gram-positive, pleomorphic rods in human gingival crevice. Bull Tokyo Med Dent Univ 27:63–70.
    OpenUrlPubMed
  180. 180.↵
    1. Moore WE,
    2. Holdeman LV,
    3. Cato EP,
    4. Good IJ,
    5. Smith EP,
    6. Ranney RR,
    7. Palcanis KG
    . 1984. Variation in periodontal floras. Infect Immun 46:720–726.
    OpenUrlAbstract/FREE Full Text
  181. 181.↵
    1. Mantzourani M,
    2. Gilbert SC,
    3. Sulong HN,
    4. Sheehy EC,
    5. Tank S,
    6. Fenlon M,
    7. Beighton D
    . 2009. The isolation of bifidobacteria from occlusal carious lesions in children and adults. Caries Res 43:308–313. doi:10.1159/000222659.
    OpenUrlCrossRefPubMed
  182. 182.↵
    1. Utto P,
    2. Teanpaisan R,
    3. Piwat S,
    4. Chandeying V
    . 2017. Assessment of prevalence, adhesion and surface charges of Bifidobacterium spp. isolated from Thai women with bacterial vaginosis and healthy women. J Med Assoc Thai 100:1–8.
    OpenUrl
  183. 183.↵
    1. Utto P,
    2. Piwat S,
    3. Teanpaisan R
    . 2016. Prevalence and adhesion properties of oral bifidobacterium species in caries-active and caries-free Thai children. Walailak J Sci Technol 14:645–653.
    OpenUrl
  184. 184.↵
    1. Jäsberg H,
    2. Soderling E,
    3. Endo A,
    4. Beighton D,
    5. Haukioja A
    . 2016. Bifidobacteria inhibit the growth of Porphyromonas gingivalis but not of Streptococcus mutans in an in vitro biofilm model. Eur J Oral Sci 124:251–258. doi:10.1111/eos.12266.
    OpenUrlCrossRef
  185. 185.↵
    1. Aas JA,
    2. Griffen AL,
    3. Dardis SR,
    4. Lee AM,
    5. Olsen I,
    6. Dewhirst FE,
    7. Leys EJ,
    8. Paster BJ
    . 2008. Bacteria of dental caries in primary and permanent teeth in children and young adults. J Clin Microbiol 46:1407–1417. doi:10.1128/JCM.01410-07.
    OpenUrlAbstract/FREE Full Text
  186. 186.↵
    1. Engevik MA,
    2. Engevik KA,
    3. Yacyshyn MB,
    4. Wang J,
    5. Hassett DJ,
    6. Darien B,
    7. Yacyshyn BR,
    8. Worrell RT
    . 2015. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. Am J Physiol Gastrointest Liver Physiol 308:G497–G509. doi:10.1152/ajpgi.00090.2014.
    OpenUrlCrossRefPubMed
  187. 187.↵
    1. Engevik MA,
    2. Yacyshyn MB,
    3. Engevik KA,
    4. Wang J,
    5. Darien B,
    6. Hassett DJ,
    7. Yacyshyn BR,
    8. Worrell RT
    . 2015. Human Clostridium difficile infection: altered mucus production and composition. Am J Physiol Gastrointest Liver Physiol 308:G510–G524. doi:10.1152/ajpgi.00091.2014.
    OpenUrlCrossRefPubMed
  188. 188.↵
    1. Tkachenko A,
    2. Da Silva L,
    3. Hearne J,
    4. Parveen S,
    5. Waguespack Y
    . 2013. An assay to screen bacterial adhesion to mucus biomolecules. Lett Appl Microbiol 56:79–82. doi:10.1111/lam.12003.
    OpenUrlCrossRef
  189. 189.↵
    1. Starkey BJ,
    2. Snary D,
    3. Allen A
    . 1972. Fractionation of water-soluble pig gastric mucus by equilibrium density-gradient centrifugation in caesium chloride. Biochem J 128:123P.
    OpenUrlFREE Full Text
  190. 190.↵
    1. Bianchi MA,
    2. Del Rio D,
    3. Pellegrini N,
    4. Sansebastiano G,
    5. Neviani E,
    6. Brighenti F
    . 2004. A fluorescence-based method for the detection of adhesive properties of lactic acid bacteria to Caco-2 cells. Lett Appl Microbiol 39:301–305. doi:10.1111/j.1472-765X.2004.01589.x.
    OpenUrlCrossRefPubMed
  191. 191.↵
    1. Miyanaga K,
    2. Takano S,
    3. Morono Y,
    4. Hori K,
    5. Unno H,
    6. Tanji Y
    . 2007. Optimization of distinction between viable and dead cells by fluorescent staining method and its application to bacterial consortia. Biochem Eng J 37:56–61. doi:10.1016/j.bej.2007.03.007.
    OpenUrlCrossRef
  192. 192.↵
    1. Mitrovic S,
    2. Nogueira C,
    3. Cantero-Recasens G,
    4. Kiefer K,
    5. Fernandez-Fernandez JM,
    6. Popoff JF,
    7. Casano L,
    8. Bard FA,
    9. Gomez R,
    10. Valverde MA,
    11. Malhotra V
    . 2013. TRPM5-mediated calcium uptake regulates mucin secretion from human colon goblet cells. Elife 2:e00658. doi:10.7554/eLife.00658.
    OpenUrlCrossRefPubMed
  193. 193.↵
    1. Hoque KM,
    2. Woodward OM,
    3. van Rossum DB,
    4. Zachos NC,
    5. Chen L,
    6. Leung GP,
    7. Guggino WB,
    8. Guggino SE,
    9. Tse CM
    . 2010. Epac1 mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion. J Gen Physiol 135:43–58. doi:10.1085/jgp.200910339.
    OpenUrlAbstract/FREE Full Text
  194. 194.↵
    1. Ouwehand AC,
    2. Grasten S,
    3. Niemi P,
    4. Mykkanen H,
    5. Salminen S
    . 2000. Wheat or rye supplemented diets do not affect faecal mucus concentration or the adhesion of probiotic micro-organisms to faecal mucus. Lett Appl Microbiol 31:30–33. doi:10.1046/j.1472-765x.2000.00758.x.
    OpenUrlCrossRefPubMed
  195. 195.↵
    1. Perry JL,
    2. Ramachandran NK,
    3. Utama B,
    4. Hyser JM
    . 2015. Use of genetically-encoded calcium indicators for live cell calcium imaging and localization in virus-infected cells. Methods 90:28–38. doi:10.1016/j.ymeth.2015.09.004.
    OpenUrlCrossRef
  196. 196.
    1. Kreymborg K,
    2. Etzensperger R,
    3. Dumoutier L,
    4. Haak S,
    5. Rebollo A,
    6. Buch T,
    7. Heppner FL,
    8. Renauld JC,
    9. Becher B
    . 2007. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 179:8098–8104. doi:10.4049/jimmunol.179.12.8098.
    OpenUrlAbstract/FREE Full Text
  197. 197.
    1. Maresz K,
    2. Ponomarev ED,
    3. Barteneva N,
    4. Tan Y,
    5. Mann MK,
    6. Dittel BN
    . 2008. IL-13 induces the expression of the alternative activation marker Ym1 in a subset of testicular macrophages. J Reprod Immunol 78:140–148. doi:10.1016/j.jri.2008.01.001.
    OpenUrlCrossRefPubMed
  198. 198.
    1. Verri WA, Jr.,
    2. Guerrero AT,
    3. Fukada SY,
    4. Valerio DA,
    5. Cunha TM,
    6. Xu D,
    7. Ferreira SH,
    8. Liew FY,
    9. Cunha FQ
    . 2008. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A 105:2723–2728. doi:10.1073/pnas.0712116105.
    OpenUrlAbstract/FREE Full Text
  199. 199.
    1. Hashimoto M,
    2. Tan S,
    3. Mori N,
    4. Cheng H,
    5. Cheng PW
    . 2007. Mucin biosynthesis: molecular cloning and expression of mouse mucus-type core 2 beta1,6 N-acetylglucosaminyltransferase. Glycobiology 17:994–1006. doi:10.1093/glycob/cwm068.
    OpenUrlCrossRefPubMedWeb of Science
  200. 200.
    1. Meng D,
    2. Newburg DS,
    3. Young C,
    4. Baker A,
    5. Tonkonogy SL,
    6. Sartor RB,
    7. Walker WA,
    8. Nanthakumar NN
    . 2007. Bacterial symbionts induce a FUT2-dependent fucosylated niche on colonic epithelium via ERK and JNK signaling. Am J Physiol Gastrointest Liver Physiol 293:G780–G787. doi:10.1152/ajpgi.00010.2007.
    OpenUrlCrossRefPubMedWeb of Science
  201. 201.
    1. Gaudier E,
    2. Jarry A,
    3. Blottiere HM,
    4. de Coppet P,
    5. Buisine MP,
    6. Aubert JP,
    7. Laboisse C,
    8. Cherbut C,
    9. Hoebler C
    . 2004. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol 287:G1168–G1174. doi:10.1152/ajpgi.00219.2004.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways
Melinda A. Engevik, Berkley Luk, Alexandra L. Chang-Graham, Anne Hall, Beatrice Herrmann, Wenly Ruan, Bradley T. Endres, Zhongcheng Shi, Kevin W. Garey, Joseph M. Hyser, James Versalovic
mBio Jun 2019, 10 (3) e01087-19; DOI: 10.1128/mBio.01087-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mBio article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways
(Your Name) has forwarded a page to you from mBio
(Your Name) thought you would be interested in this article in mBio.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Bifidobacterium dentium Fortifies the Intestinal Mucus Layer via Autophagy and Calcium Signaling Pathways
Melinda A. Engevik, Berkley Luk, Alexandra L. Chang-Graham, Anne Hall, Beatrice Herrmann, Wenly Ruan, Bradley T. Endres, Zhongcheng Shi, Kevin W. Garey, Joseph M. Hyser, James Versalovic
mBio Jun 2019, 10 (3) e01087-19; DOI: 10.1128/mBio.01087-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

acetate
bifidobacteria
epithelium
GABA
glycans
goblet cells
gut microbes
intestine
Muc2
mucins
probiotics

Related Articles

Cited By...

About

  • About mBio
  • Editor in Chief
  • Board of Editors
  • AAM Fellows
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Article Types
  • Ethics
  • Contact Us

Follow #mBio

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2150-7511